TL;DR: MOTS-c (Mitochondrial ORF of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome, specifically a short open reading frame (sORF) inside the 12S rRNA gene. First described by Lee et al. in Cell Metabolism (2015), it is classified as a mitochondrial-derived peptide (MDP). Preclinical research documents AMPK pathway activation, improved insulin sensitivity in skeletal muscle models, nuclear translocation under metabolic stress, and exercise-mimetic signaling. The research base is predominantly rodent and cell culture. MOTS-c is not FDA approved, has no authorized human use, and no large human RCTs have been completed as of 2026.

Research-Use Disclaimer: This article is for educational and research reference purposes only. MOTS-c is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research unless explicitly noted. For adults 21+ with a research interest only.

What Is MOTS-c? Definition, Origin, and Discovery

MOTS-c, short for Mitochondrial ORF of the 12S rRNA-c, is a 16-amino-acid peptide encoded within a short open reading frame (sORF) embedded in the mitochondrial 12S ribosomal RNA gene. It was first identified and characterized by Lee and colleagues at the University of Southern California’s Leonard Davis School of Gerontology, with the seminal paper published in Cell Metabolism in March 2015 (PMID: 25738459).

Prior to the identification of MOTS-c, it was thought that the mitochondrial genome (mtDNA) encoded only 37 genes: 22 tRNAs, 2 rRNAs, and 13 mRNAs. The discovery of humanin, a peptide encoded in the 16S rRNA region of the mtDNA, suggested the mitochondrial genome might contain additional functional sORFs. Lee et al. (2016) in Free Radical Biology and Medicine described MOTS-c as evidence of a larger mitochondrial genetic repertoire, expanding the known coding capacity of the organelle that was once considered metabolically passive at the genetic level.

MOTS-c is co-localized with mitochondria across various tissues and is detectable in plasma. Zheng et al. (2023) in Frontiers in Endocrinology reviewed evidence indicating that circulating MOTS-c levels decline with age, a finding that has attracted interest in the context of aging biology research.

What Mechanisms Has MOTS-c Research Documented?

MOTS-c does not appear to act through a single receptor. Peer-reviewed research has described several intersecting pathways through which it exerts documented effects in preclinical models. The four most consistently reported mechanisms are detailed below.

1. AMPK Activation via the Folate-AICAR Pathway

The foundational 2015 Cell Metabolism study by Lee et al. described MOTS-c’s primary cellular mechanism: inhibition of the folate cycle and its tethered de novo purine biosynthesis pathway. This inhibition elevates cellular AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a known AMPK activator. The result is activation of AMPK (AMP-activated protein kinase), the central energy-sensing enzyme that regulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Lee et al. found that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity, through this mechanism.

A 2023 review by Wan et al. in Journal of Translational Medicine characterized this as the “Folate-AICAR-AMPK pathway” and reviewed evidence that it underlies MOTS-c’s documented influences on energy metabolism, insulin resistance, and stress homeostasis.

2. Nuclear Translocation Under Metabolic Stress

A key mechanistic finding published in Cell Metabolism in 2018 by Kim, Son, Benayoun, and Lee demonstrated that MOTS-c is not confined to the mitochondria. Under conditions of metabolic stress (including glucose restriction), MOTS-c translocates from the mitochondria to the nucleus, where it regulates nuclear gene expression in an AMPK-dependent manner. In the nucleus, MOTS-c was found to regulate genes containing antioxidant response elements (ARE) and to interact with the stress-responsive transcription factor NRF2 (nuclear factor erythroid 2-related factor 2). This represented what the authors described as evidence that the mitochondrial and nuclear genomes “co-evolved to independently encode for factors to cross-regulate each other”, a concept termed mitonuclear communication.

3. Insulin Sensitivity and Metabolic Regulation in Skeletal Muscle

The primary target organ identified in MOTS-c research is skeletal muscle. The 2015 Lee et al. study found that MOTS-c’s primary cellular activity was concentrated in muscle tissue, with enhanced glucose uptake documented in skeletal muscle cell models. Yin et al. (2021) in Pharmacological Research extended these findings to a gestational diabetes mouse model, finding that MOTS-c administration significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and activated insulin signaling in skeletal muscle of the GDM mouse model, alongside apparent protection of pancreatic beta-cells from injury.

Mohtashami et al. (2022) in International Journal of Molecular Sciences reviewed MOTS-c’s role across age-related diseases, characterizing aging as associated with gradual loss of mitochondrial metabolic balance and noting that MOTS-c treatment in animal models has been studied as a potential countermeasure to age-related declines in muscle homeostasis and metabolic function.

4. Exercise-Mimetic Signaling

MOTS-c has been described in the literature as an “exercise-mimetic” signal, a compound whose documented biological actions parallel some of the metabolic adaptations produced by physical exercise. Lee, Kim, and Cohen (2016) described MOTS-c as implicating “the regulation of obesity, diabetes, exercise, and longevity, representing an entirely novel mitochondrial signaling mechanism.” The Wan et al. (2023) review in Journal of Translational Medicine further noted that MOTS-c expression is significantly upregulated in response to exercise and translocated to the nucleus during both exercise and metabolic stress conditions, suggesting a role in mediating some of the beneficial metabolic adaptations associated with physical activity, in preclinical contexts.

5. Cardiovascular and Anti-Inflammatory Research Contexts

More recent preclinical studies have examined MOTS-c in cardiovascular models. Zhong et al. (2022) in the Journal of Cellular and Molecular Medicine reported that MOTS-c peptide attenuated pressure overload-induced cardiac dysfunction and remodelling in a mouse model of heart failure, with AMPK pathway activation, reduced inflammatory response, and upregulated antioxidant capacity documented as associated mechanisms. Lu et al. (2023) in the European Journal of Pharmacology found decreased circulating MOTS-c levels in patients undergoing off-pump coronary artery bypass surgery who developed acute lung injury, and in animal models, MOTS-c suppressed ferroptosis (an iron-dependent form of cell death) via a PPARγ signaling pathway. All findings are from preclinical or observational contexts.

What Is MOTS-c’s Evidence Tier? An Honest Assessment

Accurately representing the state of MOTS-c evidence is essential for anyone discussing this compound in a research context. The following table summarizes the landscape as of 2026:

The honest limitation to state clearly: MOTS-c research is an active and growing field, but it remains predominantly at the preclinical stage. Rodent metabolic models and cell culture findings do not guarantee translation to human physiology. The molecular mechanisms, particularly AMPK activation and nuclear translocation, are well-characterized at a mechanistic level, but efficacy and safety in humans has not been established through controlled clinical trials. The exercise-mimetic framing, while compelling as a research hypothesis, is based on mechanistic parallels and animal data rather than human interventional evidence.

What Is MOTS-c’s Regulatory Status?

FDA (United States)

MOTS-c is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no approved indication, no authorized dosing protocol for human use, and is classified as a research compound. Researchers should consult current FDA guidance and applicable regulations directly.

Research Classification

MOTS-c occupies the same general regulatory category as other mitochondrial-derived peptides: it is an investigational compound studied in preclinical models, with no pathway to human therapeutic use that has been authorized by any major regulatory body as of 2026. Unlike some research peptides that have entered Phase I/II clinical trials, MOTS-c has not advanced to registered human interventional trials.

Frequently Asked Questions About MOTS-c

What is MOTS-c?

MOTS-c (Mitochondrial ORF of the 12S rRNA-c) is a 16-amino-acid peptide encoded within a short open reading frame (sORF) in the mitochondrial 12S rRNA gene. It was first described by Lee et al. in Cell Metabolism (2015) and is classified as a mitochondrial-derived peptide (MDP), the second MDP identified after humanin. Its primary documented target organ in preclinical research is skeletal muscle.

Is MOTS-c FDA approved?

No. MOTS-c is not approved by the FDA for any therapeutic use in humans. It is a research compound studied predominantly in preclinical rodent and cell culture models. There is no authorized human dosing protocol, no approved clinical indication, and it is not legally available as a drug or dietary supplement in the United States.

What does MOTS-c do in research models?

In preclinical research, MOTS-c has been documented to activate AMPK via inhibition of the folate cycle and de novo purine biosynthesis; improve insulin sensitivity in skeletal muscle models; translocate to the nucleus under metabolic stress to regulate genes with antioxidant response elements; and reduce markers of obesity and insulin resistance in high-fat-diet mouse models. These findings originate from rodent and cell culture research.

What is MOTS-c’s evidence tier?

MOTS-c is a predominantly preclinical compound, multiple peer-reviewed animal and cell-culture studies have been published, but large human randomized controlled trials have not been conducted as of 2026. Plasma MOTS-c levels have been measured in humans in observational contexts (e.g., declining with age, reduced in surgical patients with lung injury), but these do not constitute interventional clinical evidence of efficacy or safety.

Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources on PubMed and publisher DOIs, read them in full. Must be 21+.

TL;DR: KPV (lysine-proline-valine) is a three-amino-acid tripeptide corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical research, primarily in vitro and murine colitis models, KPV has been documented to inhibit NF-κB and MAP kinase inflammatory signaling pathways, and to enter intestinal epithelial and immune cells via the oligopeptide transporter PepT1. The research base is predominantly preclinical. KPV is not FDA approved, not approved for human use, and represents an early-stage area of basic research investigation.

Research-Use Disclaimer: This article is for educational and research reference purposes only. KPV is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.

What Is KPV? Definition and Structural Identity

KPV is a tripeptide, a chain of three amino acids, with the sequence Lys-Pro-Val (lysine-proline-valine). Its significance in the research literature derives from its structural relationship to alpha-melanocyte-stimulating hormone (α-MSH): KPV constitutes the C-terminal three residues (positions 11–13) of this 13-amino-acid neuropeptide hormone.

Alpha-MSH is itself derived from the precursor protein proopiomelanocortin (POMC) by post-translational processing. The full α-MSH hormone exerts anti-inflammatory effects through binding to melanocortin receptors (MC1R through MC5R), which are expressed across immune system cells, skin, and nervous tissue. KPV, being only the terminal fragment, lacks the sequence motif required to bind classical melanocortin receptors, yet published preclinical research has documented that it retains substantial anti-inflammatory activity through distinct mechanisms.

In the research literature, this fragment is sometimes identified as α-MSH(11–13). The absence of melanocortin receptor binding is a defining feature that separates its research profile from that of the full α-MSH molecule, including the absence of pigmentary (melanogenic) effects that limit the clinical development of the full hormone.

What Anti-Inflammatory Mechanisms Has KPV Research Documented?

Based on articles retrieved from PubMed, preclinical research has proposed and examined several mechanistic pathways through which KPV exerts anti-inflammatory effects in experimental models. The most consistently documented are summarized below.

1. NF-κB and MAP Kinase Pathway Inhibition

The most detailed mechanistic investigation of KPV published to date is a 2008 study by Dalmasso, Charrier-Hisamuddin, Nguyen, Yan, Sitaraman, and Merlin in Gastroenterology. Using human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and human T cells (Jurkat) stimulated with pro-inflammatory cytokines, the researchers found that nanomolar concentrations of KPV inhibited NF-κB activation and MAP kinase inflammatory signaling pathways, and reduced pro-inflammatory cytokine secretion. The NF-κB inhibition was assessed via luciferase gene reporter, Western blot, and real-time RT-PCR. This study (PMID 18061177) established the core mechanistic framework that subsequent KPV research has built upon.

2. PepT1-Mediated Cellular Uptake in the Gut

The same 2008 Gastroenterology study by Dalmasso et al. also characterized the cellular entry mechanism for KPV in intestinal tissue. The investigators used radiolabeled substrate competition and [³H]KPV uptake kinetic experiments to demonstrate that KPV enters intestinal epithelial and immune cells via PepT1, the oligopeptide transporter (SLC15A1) that is normally expressed in the small intestine and is upregulated in the colon during inflammatory bowel disease. This transporter-mediated uptake mechanism is significant because PepT1 overexpression in inflamed colonic tissue may concentrate KPV specifically at sites of active inflammation.

The diagnostic relevance of PepT1-KPV interaction was further confirmed in a 2017 study by Zeng et al. in ACS Applied Materials & Interfaces, which developed a fluorescent probe (DCM-KPV) exploiting PepT1’s selectivity for KPV to visualize and distinguish between chronic and acute ulcerative colitis in cell and animal models. The probe’s specificity confirmed that KPV’s accumulation in colonic tissue is transporter-dependent (PMID 28349696).

3. Efficacy in Murine Colitis Models

Following the mechanistic work, Dalmasso et al. (2008) reported that oral administration of KPV in drinking water reduced the incidence of both DSS-induced and TNBS-induced colitis in mice, as assessed by histologic scoring and pro-inflammatory cytokine mRNA expression. These are two well-characterized rodent models used to study intestinal inflammation; findings from these models are considered preclinical data and do not constitute clinical evidence for use in human inflammatory bowel disease.

4. Nanoparticle Delivery Enhances Efficacy in Murine Models

A 2010 study by Laroui, Dalmasso, Nguyen, Yan, Sitaraman, and Merlin in Gastroenterology explored whether encapsulating KPV in targeted nanoparticles could improve delivery to inflamed colonic tissue. Using a polysaccharide hydrogel system (alginate-chitosan) to encapsulate KPV-loaded nanoparticles, the researchers found that NP-KPV reduced inflammatory parameters in the DSS-induced colitis mouse model at a concentration 12, 000-fold lower than that required for free KPV in solution to achieve similar efficacy (PMID 19909746). This concentration differential was attributed to enhanced delivery precision to the colonic mucosa rather than to increased potency of the compound itself.

5. Role of PepT1 in Colitis-Associated Tumorigenesis Research

A 2016 study by Viennois, Ingersoll, Ayyadurai, Zhao, Wang, Zhang, Han, Garg, Xiao, and Merlin in Cellular and Molecular Gastroenterology and Hepatology investigated the role of PepT1 in colitis-associated cancer (CAC) using transgenic mice overexpressing human PepT1 in intestinal epithelial cells and PepT1-knockout mice. The study found that administration of KPV prevented carcinogenesis in wild-type mice subjected to AOM/DSS treatment, but this inhibitory effect was absent in PepT1-knockout mice, confirming that KPV’s anti-inflammatory activity in these colitis models is transporter-dependent (PMID 27458604). Human colonic biopsy analysis in the same study detected increased PepT1 expression in colorectal cancer tissue, which the authors noted as a potential future target. This is a research observation and does not constitute clinical evidence for any therapeutic application.

6. Anti-Inflammatory Activity Independent of Melanocortin Receptors

Two reviews in the broader α-MSH literature have characterized the mechanistic separation between the full hormone and its KPV fragment. A 2007 review by Luger and Brzoska in Annals of the Rheumatic Diseases documented that most of the anti-inflammatory activities of α-MSH can be attributed to its C-terminal tripeptide KPV, which lacks the sequence motif for melanocortin receptor binding yet modulates NF-κB activation, adhesion molecule expression, pro-inflammatory cytokine production, and inflammatory cell migration (PMID 17934097). A 2010 review by Brzoska, Böhm, Lügering, Loser, and Luger in Advances in Experimental Medicine and Biology further characterized KPV and the related tripeptide KdPT as promising candidates for anti-inflammatory peptide therapy on the basis of their receptor-independent signaling, lack of pigmentary activity, and favorable physicochemical properties in preclinical frameworks (PMID 21222263).

7. Neuroprotective Context: α-MSH(11–13) in Traumatic Brain Injury Models

A 2013 study by Schaible et al. in PLoS One investigated the KPV-equivalent fragment α-MSH(11–13) in a controlled cortical impact (CCI) mouse model of traumatic brain injury. A single intraperitoneal administration of 1 mg/kg resulted in reduced secondary lesion volume, reduced microglia activation, and reduced neuronal apoptosis compared to controls (PMID 23940690). The authors noted increased MC1R expression in the injured brain tissue over the 48-hour post-injury window and proposed that neuroprotection may involve partial MC1R engagement in the CNS injury context, even for the short fragment. This study represents a separate research context from the intestinal inflammation literature and underscores that KPV/α-MSH(11–13) has been studied across multiple preclinical inflammation models.

What Is KPV’s Evidence Tier? An Honest Assessment

Accurate representation of the evidence state for KPV requires acknowledging that the published research is almost entirely preclinical. The table below summarizes the landscape:

The critical limitation to state plainly: In vitro cell culture results and murine colitis models, even well-designed ones, do not predict human efficacy or safety. Rodent intestinal physiology, transporter expression profiles, and immune responses differ meaningfully from those in humans. The KPV research base is noteworthy for its internal mechanistic consistency and cross-model replication at the preclinical level, but the complete absence of human clinical trial data means its efficacy and safety profile in humans is scientifically unestablished.

What Is KPV’s Regulatory and Research Status?

FDA (United States)

KPV is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has not entered late-stage clinical trials and has no approved indication, no authorized human dosing protocol, and no regulatory pathway established as of 2026. Researchers should consult current FDA guidance directly for the most current status.

Research Classification

KPV is a preclinical research compound. Its published literature is primarily from academic gastroenterology, immunology, and pharmacology groups studying intestinal inflammation and peptide delivery mechanisms. It does not appear on the WADA Prohibited List by name; however, compounds with unapproved status are subject to WADA’s Section S0 provisions for athletes.

Frequently Asked Questions About KPV

What is KPV peptide?

KPV is a tripeptide with the sequence lysine-proline-valine (Lys-Pro-Val), corresponding to the C-terminal three residues (positions 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). Derived from the larger POMC precursor protein, KPV is studied in preclinical models for anti-inflammatory properties that do not require binding to classical melanocortin receptors.

Is KPV FDA approved?

No. KPV is not approved by the FDA for any therapeutic use in humans. It is a research compound studied in in vitro and murine models. It has no approved indication, no authorized human dosing protocol, and is not legally available as a drug or dietary supplement in the United States.

How does KPV’s anti-inflammatory mechanism work?

Based on preclinical research, KPV has been documented to inhibit NF-κB activation and MAP kinase signaling in intestinal epithelial and immune cell models at nanomolar concentrations, reducing pro-inflammatory cytokine secretion. Cellular uptake in gut tissue is mediated by the oligopeptide transporter PepT1, which is overexpressed in inflamed colonic tissue. These are in vitro and animal model findings; human mechanistic data is not established.

What is KPV’s evidence tier for research?

Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Study findings in murine and cell culture models do not represent expected outcomes in humans. Must be 21+.

TL;DR: GHK-Cu is the copper(II) chelate of glycyl-L-histidyl-L-lysine, a tripeptide naturally present in human plasma that declines with age. It is one of the most extensively studied copper-binding peptides in cosmetic science, with documented actions in collagen and glycosaminoglycan synthesis, extracellular matrix remodeling, and broad gene-expression modulation. It appears in topical cosmetic products as a regulated cosmetic ingredient. It is not FDA approved as a drug and is not listed as a specifically named prohibited substance on the WADA Prohibited List.

Research-Use Disclaimer: This article is for educational and research reference purposes only. GHK-Cu is a research compound. In topical cosmetic applications it is regulated as a cosmetic ingredient; it is not approved by the FDA as a drug for any therapeutic indication. This content does not constitute medical advice, does not recommend or endorse human administration of any compound as a therapeutic agent, and does not describe protocols for personal use. All study findings described below refer to published scientific research. For adults 21+ with a research interest only.

What Is GHK-Cu? Definition and Origins

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (sequence: Gly-His-Lys), complexed with a copper(II) ion. The parent tripeptide GHK occurs naturally in human plasma, saliva, and urine, and was first isolated and characterized in 1973 by Loren Pickart, who identified it as a factor in human albumin that caused old human liver tissue to synthesize proteins at rates resembling younger tissue.

GHK has an exceptionally high affinity for copper(II) ions. When chelated, the resulting GHK-Cu complex is the biologically active form most commonly referenced in the research literature. Plasma concentrations of GHK are estimated to average approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60, a trajectory described by Dou et al. (2020) in Aging Pathobiology and Therapeutics as a rationale for further investigation of the peptide in the context of age-associated changes.

What Mechanisms Has GHK-Cu Research Documented?

GHK-Cu’s research profile spans multiple biological mechanisms. Unlike many research peptides with a single proposed receptor target, GHK-Cu’s literature documents a range of downstream effects, with Pickart and colleagues proposing broad gene-expression modulation as a unifying explanation. The key documented mechanisms are outlined below.

1. Collagen and Extracellular Matrix Stimulation

One of the foundational findings in GHK-Cu research is its capacity to stimulate connective tissue accumulation in vivo. A landmark 1993 study by Maquart et al., published in the Journal of Clinical Investigation, used a subcutaneous wound chamber model in rats and reported concentration-dependent increases in dry weight, total protein, collagen, DNA, and glycosaminoglycan content in GHK-Cu-injected chambers. Collagen synthesis was stimulated at twice the rate of non-collagen proteins, and type I and type III collagen mRNAs were elevated, while TGF-β mRNAs were not, suggesting a mechanism independent of classical TGF-β collagen induction (PMID: 8227353).

A 1992 study by Wegrowski et al. in Life Sciences further documented that GHK-Cu induced a dose-dependent increase in glycosaminoglycan (GAG) synthesis in normal human fibroblast cultures, with a biphasic response peaking at 10⁻⁹ to 10⁻⁸ M. The effect was most pronounced for extracellular dermatan sulfate and cell-layer heparan sulfate. The authors proposed GAG stimulation as one mechanism underlying the peptide’s wound-healing properties (PMID: 1522753).

2. Matrix Metalloproteinase Modulation

A 1999 study by Siméon et al. in the Journal of Investigative Dermatology examined GHK-Cu’s effects on matrix metalloproteinase (MMP) expression in rat wound chambers. The research found that while GHK-Cu did not alter interstitial collagenase activity, it increased pro-MMP-2 and activated MMP-2 during later stages of healing, suggesting a role in the remodeling phase of wound repair rather than initial collagen deposition alone (PMID: 10383745). This bidirectional regulation, stimulating both synthesis and breakdown of matrix components, is a consistently cited feature of GHK-Cu’s proposed mechanism and appears in Pickart et al.’s 2015 review in BioMed Research International.

3. Broad Gene Expression Modulation

A key theme in Pickart and Margolina’s published reviews is GHK-Cu’s proposed capacity to modulate a large number of human genes. A 2015 review by Pickart, Vasquez-Soltero, and Margolina in BioMed Research International synthesized decades of in vitro and in vivo research, describing GHK-Cu as capable of up- and downregulating at least 4, 000 human genes in cell-culture and rodent models, including genes associated with collagen synthesis, metalloproteinase activity, skin regeneration, and wound repair. The review also documented cosmetic-application findings including observations of improved skin elasticity, reduced photodamage, and increased keratinocyte proliferation in product-use studies (PMID: 26236730).

A 2012 review by the same authors in Oxidative Medicine and Cellular Longevity traced GHK’s discovery to its broad gene-regulation profile, proposing that the peptide’s ability to up- and downregulate large numbers of human genes critical for neuronal development, antioxidant defense, and maintenance of tissue homeostasis warranted further investigation (PMID: 22666519).

4. Antioxidant and Anti-Inflammatory Activity

Multiple studies have examined GHK-Cu’s antioxidant and anti-inflammatory properties. A 2019 study by Ma et al. in Life Sciences investigated GHK-Cu in a bleomycin-induced pulmonary fibrosis mouse model, finding that GHK-Cu reduced inflammatory cytokines (TNF-α and IL-6), inhibited oxidative stress markers, and partially suppressed fibrotic progression via Nrf2, NF-κB, and TGF-β1/Smad2/3 pathways (PMID: 31809714). A 2026 study by Hu et al. in the European Journal of Pharmacology using a zebrafish larvae model found that GHK-Cu decreased neutrophil and macrophage migration, suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reduced reactive oxygen species, and downregulated the JAK1 pathway, characterizing the compound as a dual anti-inflammatory and antioxidant cosmetic ingredient candidate (PMID: 41997403).

5. Wound Healing and Angiogenic Activity

In addition to the collagen-synthesis findings, GHK-Cu has been studied in angiogenic and wound-closure contexts. A 2022 study by Yang et al. in Macromolecular Bioscience investigated a GHK-functionalized hydrogel scaffold in healthy and diabetic mouse wound models, reporting significantly accelerated wound closure, collagen deposition, tissue remodeling, and upregulated eNOS and CD31 expression in the treatment group (PMID: 35598070). A 2025 study by Chen et al. in Biomaterials Research evaluated a GHK-Cu-loaded hydrogel dressing, documenting antibacterial, anti-inflammatory, hemostatic, and neovascularization-promoting effects in an infected wound model (PMID: 39902373).

A 2014 preformulation study by Badenhorst et al. in Pharmaceutical Development and Technology characterized GHK-Cu’s physicochemical properties relevant to topical delivery, finding it to be highly hydrophilic (log D between −2.38 and −2.49 at physiological pH) and relatively stable at neutral-to-acidic pH, providing foundational data for topical formulation development (PMID: 25384620; DOI: 10.3109/10837450.2014.979944).

What Is GHK-Cu’s Evidence Tier? An Honest Assessment

GHK-Cu’s evidence landscape is notably different from most research peptides studied exclusively in rodent injury models. Its cosmetic-ingredient status means a meaningful body of human-use observational and small-scale clinical data exists alongside the preclinical literature. The following table summarizes the documented evidence as of 2026.

Critical context: GHK-Cu’s topical cosmetic-ingredient status is meaningfully different from its use as a systemic or injectable research compound. Cosmetic-use data (topical application, skin outcomes) does not establish efficacy or safety for systemic use. In vitro gene-expression data, while striking in breadth, reflects cell-culture conditions that may not translate to in vivo human biology. The evidence base is stronger than many research peptides at the observational and in vitro level, but large drug-indication RCTs have not been conducted.

What Is GHK-Cu’s Regulatory Status?

FDA (United States)

GHK-Cu is used as a cosmetic ingredient in the United States, where it is regulated under the FDA’s cosmetic framework, meaning manufacturers are not required to demonstrate efficacy before sale, and label claims are limited to cosmetic (not drug) claims. GHK-Cu is not approved as a drug for any therapeutic indication. It has no IND (Investigational New Drug) designation on record for human drug development, no authorized therapeutic dosing protocol, and no approved drug label. Regulatory status should be verified against current FDA guidance, as it is subject to change.

WADA (World Anti-Doping Agency)

Based on the 2026 WADA Prohibited List, GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is not listed as a specifically named prohibited substance. This differs from compounds such as BPC-157, which are explicitly named under Section S0. However, athletes subject to WADA rules should consult the current Prohibited List and their national anti-doping organization directly, as the S0 category prohibits any pharmacological substance not approved by a regulatory authority for human therapeutic use when that substance is used as a drug, and the list is updated annually.

Frequently Asked Questions About GHK-Cu

What is GHK-Cu?

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, naturally present in human plasma. Plasma levels average approximately 200 ng/mL at age 20 and decline to roughly 80 ng/mL by age 60. The chelated form (GHK-Cu) is the biologically active version documented in extracellular matrix remodeling, collagen synthesis, antioxidant, and broad gene-expression research contexts.

Is GHK-Cu FDA approved?

GHK-Cu is not FDA approved as a drug for any therapeutic indication. It is regulated as a cosmetic ingredient when used in topical products in the United States. No approved drug label, authorized therapeutic dosing protocol, or IND designation exists for human drug use.

Is GHK-Cu on the WADA Prohibited List?

As of the 2026 WADA Prohibited List, GHK-Cu is not listed as a specifically named prohibited substance. Athletes subject to WADA rules should verify against the current list and consult their national anti-doping authority, as the S0 category has broad scope and the list changes annually.

What does the GHK-Cu research actually show?

Based on articles retrieved from PubMed, the peer-reviewed literature documents GHK-Cu’s association with increased collagen and glycosaminoglycan synthesis in vitro, MMP modulation in wound-chamber models, upregulation of thousands of human genes in cell-culture studies, antioxidant and anti-inflammatory activity across zebrafish and mouse models, and accelerated wound closure in diabetic animal models. GHK-Cu also has more human cosmetic-application data than most research peptides, including topical-use observations of improved skin firmness and reduced photodamage. Large placebo-controlled drug-indication RCTs have not been conducted.

Research use only. Not intended for human use as a drug or therapeutic agent. Not FDA approved as a drug. GHK-Cu is regulated as a cosmetic ingredient in topical products; it has no approved drug indication. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound as a therapeutic agent. All citations link to primary sources, read them in full. Must be 21+.

TL;DR: Thymosin Alpha-1 (Tα1, thymalfasin) and Thymosin Beta-4 (Tβ4, commercially available as TB-500) are not related peptides and should not be discussed interchangeably. Tα1 is a 28-amino acid immune modulator that acts through Toll-like receptor signaling and dendritic cell activation, with a substantial human clinical trial record and regulatory drug approval in more than 35 countries. Tβ4 is a 43-amino acid actin-binding protein found in virtually all mammalian cells, studied primarily in preclinical tissue-repair models. The two compounds share a historical naming convention, nothing else. Neither is approved by the U.S. FDA.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Thymosin Alpha-1 and Thymosin Beta-4 / TB-500 are research compounds in the United States context. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published literature. For adults 21+ with a research interest only.

Why Do Thymosin Alpha-1 and Thymosin Beta-4 Share a Name?

The confusion between these peptides begins in mid-20th-century biochemistry. In the late 1960s and 1970s, researchers at the George Washington University, particularly Allan Goldstein and Abraham White, isolated a series of biologically active fractions from bovine thymus extracts. These were sequentially characterized and named: the first prominent fraction became “thymosin fraction 5, ” and individual components within it were designated Thymosin Alpha-1, Beta-1, Beta-4, and so on. The naming was positional and temporal, not an indicator of structural relationship or functional similarity.

Subsequent decades of research established that most of these peptides are not exclusive to the thymus, do not share primary sequences, and do not belong to the same protein family. Thymosin Alpha-1 (Tα1) emerged as a distinct thymic hormone candidate with immune-regulatory functions. Thymosin Beta-4 (Tβ4) was found to be ubiquitously expressed across virtually all mammalian nucleated cells, one of the most abundant intracellular peptides in vertebrate biology, functioning primarily as a G-actin sequestering protein. As summarized in a 2007 review by Romani et al. in Annals of the New York Academy of Sciences, based on articles retrieved from PubMed, Tα1 is produced in vivo by cleavage of prothymosin alpha in diverse mammalian tissues and qualifies as an endogenous regulator of immune homeostasis, a characterization wholly distinct from any role attributed to the beta-thymosin family (PMID: 17495242).

The practical consequence for researchers is clear: any study, review, or commercial claim about one of these compounds does not transfer to the other. Mechanism data, evidence tiers, regulatory status, and anti-doping classifications must be evaluated independently. This comparison article addresses each dimension in turn. For deeper compound-specific profiles, see the Thymosin Alpha-1 compound profile and the TB-500 compound profile.

Thymosin Alpha-1 (Tα1): Mechanism and Research Overview

Thymosin Alpha-1 is a synthetic 28-amino acid polypeptide corresponding to residues 1–28 of prothymosin alpha, originally isolated from thymic tissue. Its primary research context is immunology, specifically, its effects on innate and adaptive immune signaling through Toll-like receptor (TLR) pathways and dendritic cell (DC) function.

Toll-Like Receptor Signaling and Dendritic Cell Activation

Based on articles retrieved from PubMed, the most mechanistically specific research on Tα1 documents its role in TLR-mediated DC activation. A 2004 study by Romani et al. in Blood demonstrated that thymosin alpha-1 induces functional maturation and interleukin-12 production by dendritic cells through the p38 MAPK/NF-κB-dependent pathway via MyD88-dependent signaling involving distinct Toll-like receptors; in vivo, the synthetic peptide activated Th1-dependent antifungal immunity, accelerated myeloid cell recovery, and protected highly susceptible transplanted mice from aspergillosis (PMID: 14982877). A complementary 2007 study by Bozza et al. in International Immunology showed that thymosin alpha-1 protected mice from murine cytomegalovirus infection through activation of plasmacytoid dendritic cells via the TLR9/MyD88-dependent viral recognition pathway, leading to activation of IFN regulatory factor 7 and promotion of the IFN-α/IFN-γ effector pathway (PMID: 17804687). Together, these two studies document Tα1’s engagement of both myeloid DCs (TLR2 and related pathways) and plasmacytoid DCs (TLR9), distinct mechanistic arms explaining its broad-spectrum immunostimulatory profile across bacterial, fungal, and viral challenges.

Th1 Polarization and Immune Homeostasis

Beyond pathogen-specific contexts, Tα1 research documents a broader immune-regulatory role. The 2007 Romani et al. review in Annals of the New York Academy of Sciences synthesizes findings showing that Tα1 induces indoleamine 2, 3-dioxygenase activity in DCs, affecting tolerization toward self and microbial non-self antigens, with in vivo results including transplantation tolerance and protection from inflammatory allergy, qualifying Tα1 as an endogenous regulator of immune homeostasis (PMID: 17495242).

Human Clinical Research

Thymosin Alpha-1 has one of the larger published human clinical trial datasets of any thymic peptide. A comprehensive 2001 review by Ancell, Phipps, and Young in the American Journal of Health-System Pharmacy documents that in four randomized and controlled clinical trials enrolling 195 patients with chronic hepatitis B, one randomized controlled trial found HBV DNA clearance in 40.6% and 25.6% of patients treated with Tα1 for 6 and 12 months respectively, compared with 9.4% of untreated controls; an open-label trial found HBV DNA clearance in 53% of patients at six months; adverse effects were primarily local injection-site irritation (PMID: 11381492). In the hepatitis C context, a 2010 review by Sherman in Annals of the New York Academy of Sciences notes that earlier combination studies with IFN-α showed improved ALT normalization (71% vs. 35%) and HCV RNA clearance (65% vs. 29%) for combination therapy, though a subsequent large Phase III randomized trial failed to meet its primary endpoint of sustained virologic response, illustrating the difficulty of generalizing immunomodulator effects across heterogeneous patient populations (PMID: 20536461). In the sepsis context, a 2018 review by Pei, Guan, and Wu in Expert Opinion on Biological Therapy summarizes that single or combined treatment with Tα1 reduced the mortality rate of sepsis, improved HLA-DR expression on monocytes, and diminished the incidence of secondary infection in available clinical studies; however, sepsis is a remarkably heterogeneous syndrome, and available studies have not been able to focus specifically on immunosuppressive individuals (PMID: 30063866).

Thymosin Beta-4 (Tβ4) and TB-500: Mechanism and Research Overview

Thymosin Beta-4 is a 43-amino acid protein expressed in virtually all mammalian nucleated cells, one of the most abundant intracellular peptides in vertebrate biology. TB-500 is the commercial name for a synthetic peptide fragment corresponding to approximately amino acids 17–23 of Tβ4, selected on the basis that this region of the molecule is associated with actin-binding activity. The scientific literature is built almost entirely around full-length Tβ4; TB-500 as a specific fragment has minimal independent published research and should be distinguished from the broader Tβ4 literature when evaluating evidence claims.

G-Actin Sequestration: The Core Mechanism

The foundational mechanism of Tβ4, and the basis for all downstream tissue-repair hypotheses, is its role as the primary G-actin sequestering protein in most vertebrate cells. Actin exists in globular (G-actin, monomeric) and filamentous (F-actin, polymerized) forms. Tβ4 binds G-actin with micromolar affinity, maintaining a pool of readily available but unpolymerized actin monomers. When cells receive signals to migrate during wound healing or angiogenesis, this sequestered pool releases and polymerizes, enabling rapid cytoskeletal reorganization and directed cell motility. This mechanism has no overlap with the TLR/dendritic cell biology of Tα1.

Wound Healing, Angiogenesis, and Tissue Repair Research

Based on articles retrieved from PubMed, a landmark 2012 review by Goldstein, Hannappel, Sosne, and Kleinman in Expert Opinion on Biological Therapy, among the most comprehensive summaries of Tβ4 biology, documents that after injury, Tβ4 is released by platelets, macrophages, and other cell types to protect cells and tissues from further damage, reduce apoptosis and inflammation, bind to actin, and promote cell migration including mobilization, migration, and differentiation of stem/progenitor cells that form new blood vessels and regenerate tissue; Tβ4 also decreases the number of myofibroblasts in wounds, resulting in decreased scar formation and fibrosis; the advances in understanding Tβ4 biology have provided the scientific foundation for ongoing and projected clinical trials in dermal wound repair, corneal injury, and cardiac and CNS repair following ischemic insults (PMID: 22074294). Among these contexts, the corneal indication has advanced furthest in human clinical development: full-length Tβ4 has entered Phase 3 human clinical trials for dry eye disease and neurotrophic keratopathy, representing one of the few Tβ4-related compounds with human trial data on record.

Actin, HIF-1α, and Cell Migration Signaling

A 2010 study by Ryu, Im, and Moon in Oncology Reports documented that HIF-1α and Tβ4 expression are both increased under hypoxic conditions and that shRNA inhibition of Tβ4 decreases cell migration while exogenous Tβ4 protein attenuates that inhibition, indicating cooperative enhancement of cell migration by Tβ4 and HIF-1α (PMID: 20878135). This illustrates that Tβ4’s role in cell motility intersects with hypoxic and angiogenic signaling, a mechanistic context entirely separate from Tα1’s immune biology.

Head-to-Head Comparison: Thymosin Alpha-1 vs. Thymosin Beta-4

The following table documents the documented differences between Tα1 and Tβ4/TB-500 across the dimensions most relevant for research literature interpretation:

Interpreting the Evidence: What the Non-Overlap Means

Because these peptides operate through entirely different pathways, the research literature on each is almost entirely non-overlapping. A review article on Tβ4 and wound healing contains no information relevant to Tα1’s TLR biology, and vice versa. Conflating the two because of the shared “thymosin” label in commercial contexts produces a scientifically incoherent evidence claim.

Frequently Asked Questions

Are Thymosin Alpha-1 and Thymosin Beta-4 the same peptide?

No. They are entirely different peptides that share only a historical naming convention. Thymosin Alpha-1 (Tα1) is a 28-amino acid thymic immune modulator acting through Toll-like receptor signaling and dendritic cell activation. Thymosin Beta-4 (Tβ4) is a 43-amino acid G-actin sequestering protein found ubiquitously in mammalian cells, studied in tissue-repair contexts. They differ in amino acid sequence, protein family, receptor targets, and clinical history. Neither the mechanism data nor the evidence base for one is transferable to the other.

Why are Thymosin Alpha-1 and Beta-4 given similar names if they are unrelated?

Both were isolated from bovine thymus extracts during early thymosin research and named sequentially within those fractions, Alpha-1 as the first well-characterized component, Beta-4 as a member of the beta-thymosin sub-series. The naming predates the molecular characterization that established they belong to different protein families. The label “thymosin” in modern research is a legacy nomenclature designation, not evidence of shared biology or mechanism.

Is Thymosin Alpha-1 (thymalfasin) approved as a drug?

Thymosin Alpha-1 (thymalfasin, trade name Zadaxin) is approved as a prescription drug for chronic hepatitis B and C in more than 35 countries. It is not approved by the U.S. FDA, and in 2023 the FDA placed it on its list of bulk drug substances that may not be compounded by U.S. 503A pharmacies. Where internationally approved, it is used as a licensed pharmaceutical under medical supervision. Regulatory approval in other jurisdictions is cited here as documented regulatory fact, not as an endorsement of any particular use of this compound.

What is the WADA status of Thymosin Alpha-1 and TB-500?

TB-500 and Thymosin beta-4 are explicitly prohibited by WADA under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable in-competition and out-of-competition. Thymosin Alpha-1 is not individually enumerated in the WADA Prohibited List as of the 2025–2026 publication; however, the S0 category captures non-approved pharmacological substances, which may apply depending on jurisdiction and regulatory context. Athletes subject to anti-doping rules should consult the current WADA Prohibited List and the WADA Global DRO tool, not this article, for definitive guidance.

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: Selank and Semax are both synthetic heptapeptides developed in Russia, but they derive from structurally unrelated parent compounds and engage distinct primary mechanisms. Selank is an analog of the immunomodulatory tetrapeptide tuftsin, documented in preclinical models for GABAergic allosteric modulation and anxiolytic-like activity. Semax is an analog of the ACTH(4-10) hormonal fragment, documented principally for upregulation of BDNF and NGF expression in the rat brain and neuroprotective effects in cerebral ischemia models. Both compounds show BDNF involvement in rodent studies, a meaningful point of overlap, but differ sharply in structural origin, primary receptor pharmacology, and the breadth of their published preclinical research. Neither is FDA approved. Both have Russian regulatory registration. The evidence base for each is concentrated in Russian academic institutions and is limited by international replication standards.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Selank and Semax are research compounds not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.

Selank vs Semax: Quick Comparison at a Glance

The table below summarizes the primary documented distinctions between Selank and Semax based on published peer-reviewed literature. This is a mechanism reference, not a clinical or therapeutic comparison.

What Is Selank? Structure and Primary Mechanism

Selank (also designated TP-7) has the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a metabolically stabilized derivative of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) cleaved from immunoglobulin G and known for macrophage activation and immune modulation. The Pro-Gly-Pro C-terminal extension was added specifically to resist the serum enzymatic degradation that rapidly limits native tuftsin’s in vivo half-life.

For a deeper profile of Selank’s mechanisms, structure, and evidence tier, see the standalone compound post: What Is Selank? Mechanism and Evidence.

Selank’s GABAergic Mechanism: What the Research Documents

The most directly characterized molecular mechanism of Selank involves positive allosteric modulation of GABA-A receptors. According to PubMed-indexed research, a 2018 radioligand-receptor study by Vyunova et al., published in Protein and Peptide Letters, demonstrated that Selank modulates [³H]GABA binding in rat brain membrane preparations in a concentration-dependent, subtype-selective manner consistent with positive allosteric modulation. The joint effect of Selank with benzodiazepines (diazepam and olanzapine) was non-cumulative and distinct from either compound alone, suggesting partially overlapping but non-identical binding sites. The investigators concluded that allosteric GABA-A modulation represents one of Selank’s primary anti-anxiety molecular mechanisms (PMID 30255741).

Supporting this GABAergic hypothesis at the gene-expression level, a 2016 study by Volkova et al., published in Frontiers in Pharmacology, used real-time PCR to analyze 84 neurotransmission-related genes in rat frontal cortex 1 and 3 hours after Selank administration. Significant changes were observed in 45 genes at 1 hour, with a positive correlation between Selank and GABA on gene expression patterns, findings the authors interpreted as consistent with GABAergic allosteric modulation (PMID 26924987).

Selank and BDNF: A Secondary but Documented Pathway

BDNF modulation is not Selank’s primary mechanistic characterization, but it has been documented in rodent models. Based on PubMed-indexed research, Inozemtseva et al. (2008), published in Doklady Biological Sciences, administered Selank intranasally to male Wistar rats and used RT-PCR and immunoenzymatic assay to measure BDNF mRNA and protein in the hippocampus in vivo, documenting that intranasal Selank produced changes in hippocampal BDNF expression (PMID 18841804). This positions BDNF as a secondary downstream feature of Selank’s mechanistic profile, relevant to the overlap discussion with Semax but not its primary pharmacological identifier.

Selank and Anxiolytic-Like Activity in Behavioral Models

Consistent with its GABAergic mechanistic profile, Selank has been evaluated in multiple rodent behavioral paradigms for anxiolytic-like activity. A 2014 study by Kolik et al. in the Bulletin of Experimental Biology and Medicine documented that a single intraperitoneal injection of Selank (0.3 mg/kg) eliminated anxiety-like behavior induced by ethanol withdrawal in alcohol-preferring rats in the elevated plus maze and social interaction tests, without affecting ethanol consumption (PMID 24913576). A 2022 study by Konstantinopolsky et al. in the same journal found that the same Selank dose reduced the total index of naloxone-precipitated morphine withdrawal syndrome by approximately 40% in morphine-dependent rats, attenuating convulsive reactions, ptosis, and postural disorders, effects described as directionally comparable to, though slightly weaker than, diazepam at 2 mg/kg (PMID 36322304). These behavioral findings are consistent with the compound’s documented GABAergic mechanism but do not establish human efficacy for any condition.

What Is Semax? Structure and Primary Mechanism

Semax has the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a synthetic analog of the N-terminal fragment spanning positions 4 through 10 of adrenocorticotropic hormone (ACTH), specifically ACTH(4-10), with a Pro-Gly-Pro C-terminal extension added for the same reason as in Selank: to confer metabolic stability in biological fluids. Despite its ACTH-derived sequence, Semax is described consistently in the published literature as “completely devoid of any hormonal activity, ” distinguishing it from ACTH itself.

Semax was developed primarily by Nikolay Myasoedov and colleagues at the Institute of Molecular Genetics, Russian Academy of Sciences. It has been registered for clinical use in Russia and studied in that context for stroke rehabilitation. For a detailed standalone profile, see: What Is Semax? Mechanism and Evidence.

Semax’s BDNF and Neurotrophin Mechanism: What the Research Shows

The most replicated and best-characterized mechanistic finding for Semax is upregulation of brain-derived neurotrophic factor (BDNF) expression in the rat brain following intranasal administration. Based on PubMed-indexed research, Dolotov et al. (2006), published in Brain Research, documented that a single intranasal Semax application (50 µg/kg) produced a maximal 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, and a 3-fold increase in exon III BDNF mRNA levels in the rat hippocampus. Semax-treated animals also showed increased conditioned avoidance reactions. The authors concluded that Semax affects cognitive brain functions by modulating hippocampal BDNF/trkB system expression and activation (PMID 16996037).

A companion 2006 study by the same group, published in the Journal of Neurochemistry, identified specific, reversible Semax binding sites on cell membranes isolated from rat basal forebrain (KD 2.4 ± 1.0 nM), and showed that intranasal Semax at 50 and 250 µg/kg produced rapid increases in BDNF protein in the basal forebrain at 3 hours post-application, without significant effects in the cerebellum, indicating region-specific activity (PMID 16635254).

Beyond BDNF, Agapova et al. (2007), published in Neuroscience Letters, documented that Semax (50 µg/kg, single intranasal application) induced rapid, gene- and region-specific changes in both BDNF and nerve growth factor (NGF) expression in intact rat brain: BDNF expression increased in hippocampus, brainstem, and cerebellum, while NGF decreased in the frontal cortex, a profile the authors characterized as selective rather than globally stimulatory (PMID 17353092).

Semax in Cerebral Ischemia Models

A distinct research strand in the Semax literature, absent in Selank’s profile, concerns neuroprotection in rodent cerebral ischemia models. Dmitrieva et al. (2009), published in Cellular and Molecular Neurobiology, examined neurotrophin and receptor gene expression following permanent middle cerebral artery occlusion in rats. Semax selectively activated transcription of BDNF, NT-3, and NGF, as well as their Trk receptors, in the ischemic rat cortex at 3, 24, and 72 hours after occlusion, a profile the authors characterized as distinct from the non-selective effects of the PGP tripeptide alone (PMID 19633950). This ischemia-model literature forms the preclinical basis for Semax’s Russian clinical registration for stroke rehabilitation.

How Do Selank and Semax Differ, and Where Do They Overlap?

The Core Mechanistic Divergence

Selank and Semax occupy distinct positions in the neuropeptide pharmacology literature despite their superficial similarities, both are synthetic Russian heptapeptides with C-terminal Pro-Gly-Pro extensions and overlapping institutional origins. The fundamental divergence is mechanistic and structural:

Selank’s primary documented pathway in rodent models is inhibitory neurotransmission modulation, specifically, positive allosteric modulation of GABA-A receptors, the same receptor family targeted by benzodiazepines. Its pharmacological comparators in the literature are diazepam and other classical anxiolytics. Its behavioral profile in rodent models is consistent with anxiolytic-like activity, not cognitive enhancement as a primary readout.

Semax’s primary documented pathway is neurotrophic signaling, specifically, upregulation of BDNF and NGF gene and protein expression in multiple brain regions following intranasal administration. Its pharmacological context in the literature is neuroprotection and cognitive facilitation, particularly in ischemia models and memory paradigms. Its behavioral comparators include piracetam and other nootropic agents, not benzodiazepines.

The BDNF Overlap: Real but Asymmetric

Both compounds have documented interactions with BDNF in rodent models, this is a genuine, not superficial, overlap. However, the nature and centrality of this overlap differ significantly between the two compounds. For Semax, BDNF upregulation is the primary and most replicated mechanistic finding across multiple independent studies. For Selank, BDNF modulation appears as a secondary, less-extensively-characterized finding documented in fewer publications, with the primary mechanism assigned to GABAergic allosteric modulation.

The shared Pro-Gly-Pro C-terminal extension is likely relevant: this tripeptide has been independently documented to have biological activity in the CNS context (Dmitrieva et al., 2009 compared Semax and PGP directly), and Selank’s metabolic fragments have also been studied for biological activity (Andreeva et al., 2010). Both compounds may share some downstream neurobiological consequences through this shared structural fragment, even though their primary parent sequences are unrelated.

Immunomodulation: Selank-Specific

One dimension of Selank’s profile that has no parallel in the Semax literature is immunomodulation. Selank’s structural derivation from tuftsin, an endogenous tetrapeptide with well-documented macrophage-stimulating and immunomodulatory functions, gives it a documented immunological dimension. Studies have examined changes in cytokine and chemokine gene expression following Selank administration in mouse models (Kolomin et al., 2011, PMID 21786679). This pathway is not a feature of Semax’s documented mechanistic profile.

Evidence Tier Comparison: An Honest Assessment

Both compounds share important structural limitations in their evidence bases that should be stated plainly. The table below summarizes the evidence landscape for each compound.

Critical limitation to state plainly: Both compounds share the same structural epistemic constraint, the published research is heavily concentrated within a small number of Russian academic institutions, primarily the Institute of Molecular Genetics and the V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Sciences. This is not evidence of fraudulent research, but it does mean that independent replication by unaffiliated Western laboratories is minimal. Rodent behavioral models of anxiety-like activity and ischemia-based neuroprotection do not reliably predict human clinical outcomes. The mechanistic findings described above are scientifically documented observations in experimental systems; they do not establish human efficacy or safety for either compound. The honest summary is that both compounds are interesting research subjects with coherent mechanistic profiles at the preclinical level, but their clinical potential in humans remains scientifically unestablished by Western evidence standards.

Regulatory Status: Both Compounds

United States (FDA)

Neither Selank nor Semax is approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. Neither has an approved human therapeutic indication, approved dosing protocol, or legal availability as a pharmaceutical in the United States. Both are classified as research compounds. Researchers should consult current FDA guidance directly.

Russia

Selank is registered in Russia as a pharmaceutical drug in nasal drops formulation for use as an anxiolytic. Semax is registered in Russia for clinical use in neurological indications, including stroke rehabilitation. These registrations reflect the regulatory framework of the Russian Ministry of Health and do not confer approval status in the United States, European Union, or other Western regulatory jurisdictions. Primary registration data for either compound is not widely accessible in the English-language literature.

Frequently Asked Questions

What is the core difference between Selank and Semax?

Do both Selank and Semax affect BDNF?

Yes, BDNF modulation is a documented point of overlap. Selank has been shown to regulate hippocampal BDNF expression following intranasal administration in rats (Inozemtseva et al., 2008; PMID 18841804). Semax’s BDNF upregulation is more extensively studied and represents its primary mechanistic characterization: a single intranasal application documented a 1.4-fold increase in hippocampal BDNF protein and a 3-fold increase in BDNF mRNA (Dolotov et al., 2006; PMID 16996037). The overlap is real but asymmetric, for Semax, BDNF upregulation is the central finding; for Selank, it is secondary to the GABAergic mechanism.

Are Selank and Semax FDA approved?

No. Neither compound is approved by the U.S. Food and Drug Administration for any therapeutic use in humans. Both are registered in Russia under different regulatory standards. Neither holds FDA or EMA approval. Both are classified as research compounds in the United States.

Where can evidence tiers for both compounds be reviewed in full?

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: Ipamorelin and CJC-1295 are both studied for their effects on growth hormone (GH) release from the anterior pituitary, but they act on two entirely different receptors. Ipamorelin is a growth hormone secretagogue (GHRP/GHS class): it acts as a selective agonist at the GHS-R1a receptor, the same receptor targeted by the endogenous hormone ghrelin. CJC-1295 is a GHRH analog: it acts at the GHRH receptor (GHRHR), which is activated by the hypothalamic hormone growth-hormone-releasing hormone. These two receptors are distinct GPCRs expressed on the same pituitary somatotroph cells, and they operate through overlapping but mechanistically separate signaling pathways. Understanding the receptor-level distinction is the starting point for any research-literature analysis of these two compounds. Neither is FDA approved; both are prohibited by WADA under Section S2.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Ipamorelin and CJC-1295 are research compounds, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical and pharmacokinetic research. For adults 21+ with a research interest only.

Quick Comparison: Ipamorelin vs CJC-1295 at a Glance

The table below summarizes the key mechanistic and pharmacological distinctions between these two compounds as documented in peer-reviewed literature. Full explanations follow in the sections below.

What Is Ipamorelin? The GHS-R1a Mechanism

Ipamorelin is a synthetic pentapeptide (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that belongs to the growth hormone secretagogue (GHS) class, a family of compounds that stimulate GH release by acting on the GHS-R1a receptor, also known as the ghrelin receptor. GHS-R1a is a G protein-coupled receptor (GPCR) expressed on somatotroph cells of the anterior pituitary gland.

The mechanistic basis for ipamorelin’s GH-releasing activity is well characterized in preclinical pharmacology literature. Based on articles retrieved from PubMed, the landmark characterization study, Raun et al. (1998), published in the European Journal of Endocrinology, demonstrated that ipamorelin stimulated GH release with potency and efficacy comparable to GHRP-6 in both anesthetized rats and conscious swine, with an ED₅₀ in swine of 2.3 nmol/kg and a peak GH of 65 ng/mL (PMID 9849822). Critically, pharmacological profiling using both GHRP-receptor antagonists and GHRH antagonists confirmed that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like (GHS-R) receptor pathway, not through the GHRH receptor.

What distinguishes ipamorelin’s selectivity profile from older GHRPs?

Ipamorelin was developed through a medicinal chemistry programme to address a limitation of earlier GHRPs: their tendency to elevate ACTH and cortisol alongside GH. The Raun et al. (1998) study found that administration of GHRP-6 and GHRP-2 to conscious swine produced significant elevations in plasma ACTH and cortisol, whereas ipamorelin did not raise ACTH or cortisol to levels significantly different from GHRH stimulation alone, even at doses more than 200-fold above the GH-releasing ED₅₀. FSH, LH, prolactin, and TSH were unaffected by ipamorelin at all doses tested. The authors described ipamorelin as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH” (PMID 9849822). This selectivity profile is a preclinical finding in swine and has not been replicated in large, placebo-controlled human clinical trials.

Ipamorelin in bone growth and body composition research

A 1999 study by Johansen et al., published in Growth Hormone & IGF Research, administered ipamorelin subcutaneously three times daily for 15 days to adult female rats and measured longitudinal bone growth rate (LGR) via intravital tetracycline labeling. Based on articles retrieved from PubMed, the study found that ipamorelin dose-dependently increased LGR from 42 µm/day in vehicle controls to 52 µm/day in the highest-dose group, with a pronounced dose-dependent effect on body weight gain (PMID 10373343). Notably, total IGF-1 levels, IGFBPs, and serum markers of bone formation and resorption were not significantly altered, and the pituitary GH response to a provocative ipamorelin dose was marginally reduced after the treatment period, consistent with receptor-level adaptation to repeated GHS-R1a stimulation.

More recently, a 2024 study by Lu et al. in Physiology & Behavior compared the GHS-R1a agonists anamorelin and ipamorelin in a ferret model of cisplatin-induced emesis and weight loss, finding that both ipamorelin and anamorelin administered intraperitoneally inhibited cisplatin-induced weight loss during the delayed phase (48–72 h) by approximately 24% (PMID 39043357). This study extends the documented research profile of GHS-R1a agonism beyond GH-axis effects into metabolic and oncology-adjacent contexts.

For deeper background on ipamorelin’s mechanism and evidence base, see the standalone compound post: What Is Ipamorelin? Mechanism and Evidence.

What Is CJC-1295? The GHRH Receptor Mechanism

CJC-1295 is a synthetic GHRH analog, a structurally modified version of the first 29 amino acids of human growth-hormone-releasing hormone (hGRF 1–29) that retains GHRH receptor agonist activity while addressing the central pharmacokinetic limitation of native GHRH: a plasma half-life of under 10 minutes, due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV).

CJC-1295 acts at the GHRH receptor (GHRHR), a G_s-coupled GPCR expressed on anterior pituitary somatotrophs. GHRHR activation triggers the adenylyl cyclase / cAMP / PKA cascade, driving both GH synthesis and pulsatile GH secretion. This signaling pathway is mechanistically distinct from the G_q/11-mediated IP3/DAG/Ca²⁺ cascade activated by GHS-R1a. Both cascades converge on GH release from the same somatotroph cell, but through separate intracellular routes.

The Drug Affinity Complex (DAC) and half-life extension

CJC-1295’s defining pharmacokinetic feature is the Drug Affinity Complex (DAC): a maleimido group at the C-terminus that, upon injection, covalently bonds to Cys34 of circulating serum albumin. Based on articles retrieved from PubMed, the synthesis and characterization study by Jetté et al. (2005), published in Endocrinology, demonstrated that the CJC-1295–albumin conjugate retained bioactivity in a GH secretion assay using cultured rat anterior pituitary cells and produced a 4-fold increase in GH area under the curve over 2 hours compared with native hGRF(1–29) in rats (PMID 15817669). The compound was detectable in rat plasma beyond 72 hours post-injection, and Western blot analysis confirmed the presence of a CJC-1295–immunoreactive band co-migrating with serum albumin as early as 15 minutes post-injection.

Human pharmacokinetic data: what the RCT evidence shows

CJC-1295 is notable in the research peptide landscape for having published human data from randomized, placebo-controlled trials, an evidence level not available for the majority of research compounds in this class. Based on articles retrieved from PubMed, the primary human pharmacokinetic reference is Teichman et al. (2006), published in the Journal of Clinical Endocrinology and Metabolism, which conducted two randomized, double-blind, placebo-controlled, ascending-dose trials in healthy subjects aged 21–61 years. The study found that after a single subcutaneous injection of CJC-1295, mean plasma GH concentrations increased 2- to 10-fold for 6 or more days, and mean plasma IGF-1 concentrations rose 1.5- to 3-fold for 9–11 days, with an estimated CJC-1295 plasma half-life of 5.8–8.1 days (PMID 16352683). No serious adverse reactions were reported at doses of 30 or 60 µg/kg.

A second human study by Ionescu and Frohman (2006), also in the Journal of Clinical Endocrinology and Metabolism, characterized GH pulsatility via 20-minute blood sampling over 12 hours in healthy men before and one week after CJC-1295 injection. The study found that GH secretory pulse frequency and magnitude were unaltered, while trough GH levels increased 7.5-fold and overall mean GH and IGF-1 levels rose approximately 46% and 45%, respectively (PMID 17018654). The preservation of pulsatility under continuous GHRH receptor stimulation, a consequence of the long half-life, was identified as a potentially important physiological characteristic of the compound’s mechanism.

Complementary preclinical evidence from Alba et al. (2006), published in the American Journal of Physiology, Endocrinology and Metabolism, demonstrated that once-daily administration of CJC-1295 normalized body weight, body length, and femur and tibia length in GHRH-knockout mice, animals that fail to achieve normal growth due to absent endogenous GHRH signaling, and increased pituitary GH mRNA, suggesting somatotroph proliferation (PMID 16822960). This preclinical model demonstrates activity at the GHRH receptor axis but should not be interpreted as evidence for human therapeutic outcomes.

For the full mechanistic and evidence profile of CJC-1295, including the DAC vs. non-DAC distinction (mod GRF 1-29), see: What Is CJC-1295? Mechanism and Evidence.

How These Two Mechanisms Differ, and Why Researchers Study Them Together

The core mechanistic distinction between ipamorelin and CJC-1295 is receptor identity. These are not two versions of the same compound; they are agonists at two different GPCRs that both regulate GH release from anterior pituitary somatotrophs:

Ipamorelin → GHS-R1a (ghrelin receptor)

GHS-R1a couples to G_q/11 proteins, triggering phospholipase C, IP3-mediated calcium release, and downstream GH pulse generation. Ipamorelin is a peptide mimic of ghrelin, a peripheral (primarily gut-derived) orexigenic peptide, acting via this receptor on the pituitary. The GHS-R1a axis is considered a nutrient-sensing and metabolic-state input to GH secretion.

CJC-1295 → GHRH receptor (GHRHR)

GHRHR couples to G_s proteins, activating adenylyl cyclase, elevating cAMP, and activating protein kinase A (PKA), which drives both GH gene expression and exocytotic GH release. CJC-1295 is a mimic of GHRH, the hypothalamic peptide that serves as the primary stimulatory signal to the pituitary in the classical hypothalamic-pituitary axis. The GHRH axis is the dominant regulatory pathway for physiological GH pulsatility.

Because GHS-R1a and GHRHR are two distinct stimulatory inputs into the same somatotroph cell, the research literature has examined the relationship between GHRH-axis and ghrelin-axis agonism as a means of characterizing how these pathways interact. The dual-receptor architecture means that activation of one pathway does not preclude simultaneous activation of the other, each receptor operates its own intracellular cascade. Researchers studying GH secretion dynamics have used co-administration of GHRH analogs and GHRPs as a model for examining additive or synergistic stimulation of both axes simultaneously. This is a documented research-literature observation. It does not constitute a protocol recommendation for human use, and nothing in this article should be interpreted as guidance on research subject administration.

Evidence by Tier: An Honest Assessment of Both Compounds

The Legendary Labz evidence-tier framework rates compounds by the strongest level of published evidence available. Both ipamorelin and CJC-1295 are currently classified as Tier 2, but for different reasons reflecting different evidence profiles. (See: How to Read an Evidence Tier.)

The critical distinction to state plainly: CJC-1295’s human RCT evidence (Teichman et al. 2006; Ionescu & Frohman 2006) documents pharmacokinetic parameters and GH/IGF-1 secretory responses, not therapeutic efficacy or clinical safety in patient populations. Ipamorelin’s human data is limited to a single dose-escalation pharmacokinetic study. Neither compound has been evaluated in large, placebo-controlled human trials designed to establish therapeutic benefit or long-term safety profiles in any population. The receptor pharmacology and preclinical data for both compounds are well-characterized; the human evidence base for downstream outcomes is not.

Ipamorelin’s selectivity advantage, its documented lack of ACTH/cortisol elevation at GH-releasing doses, is a preclinical finding in conscious swine (Raun et al., 1998). It has not been confirmed in large human trials, and preclinical pharmacology does not guarantee equivalent selectivity profiles across human physiology. Both compounds remain research-use-only compounds with no approved human therapeutic indication.

For context on related GH-axis research compounds, see: What Is Sermorelin? and What Is MK-677?

Regulatory Status: Both Compounds

FDA (United States)

Neither ipamorelin nor CJC-1295 is approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. Neither has an authorized indication, an approved dosing protocol, or lawful commercial availability as a therapeutic agent in the United States. The FDA classifies growth hormone secretagogues and GHRH analogs as compounds subject to regulatory scrutiny. Researchers should consult current FDA guidance directly for the most current regulatory standing of each compound.

WADA (World Anti-Doping Agency)

Both ipamorelin and CJC-1295 are prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics of the WADA Prohibited List. Section S2 covers all GH-releasing peptides, GHRH analogs, and their mimetics, prohibited both in-competition and out-of-competition. Validated analytical detection methods for CJC-1295 in plasma have been published and independently validated (Timms et al. 2019, PMID 30938069). Athletes subject to WADA rules are prohibited from using either compound in any context.

Frequently Asked Questions

What is the core mechanistic difference between ipamorelin and CJC-1295?

Ipamorelin is a growth hormone secretagogue: it acts as an agonist at the GHS-R1a receptor (the ghrelin receptor), a G protein-coupled receptor on anterior pituitary somatotrophs that signals via G_q/11 / calcium cascades. CJC-1295 is a GHRH analog: it acts at the GHRH receptor (GHRHR), a different GPCR on the same cell type that signals via G_s / cAMP / PKA. These are two distinct upstream inputs into the same GH-release machinery, different receptors, different signaling cascades, shared downstream output of GH secretion.

Why does CJC-1295 have a much longer half-life than ipamorelin?

CJC-1295 incorporates the Drug Affinity Complex (DAC): a maleimido group at the C-terminus that covalently binds to Cys34 of circulating serum albumin after injection (Jetté et al., 2005, PMID 15817669). The resulting CJC-1295–albumin conjugate inherits albumin’s extended circulation time, yielding a measured human plasma half-life of 5.8–8.1 days (Teichman et al., 2006, PMID 16352683). Ipamorelin has no albumin-binding modification and has a terminal half-life of approximately 2 hours in human pharmacokinetic studies. CJC-1295 without the DAC (Modified GRF 1-29) shares the structural backbone but lacks albumin binding and has a half-life of approximately 30 minutes, closer to ipamorelin’s duration range.

What makes ipamorelin more selective than older GHRPs like GHRP-6?

In the Raun et al. (1998) study in the European Journal of Endocrinology (PMID 9849822), ipamorelin did not significantly elevate ACTH or cortisol in conscious swine even at doses more than 200-fold above the GH-releasing ED₅₀. GHRP-6 and GHRP-2, tested under identical conditions, produced significant ACTH and cortisol responses. The authors attributed ipamorelin’s selectivity to its structural difference from earlier GHRPs, it lacks the central Ala-Trp dipeptide of GHRP-1, which is proposed to be involved in the off-target pituitary-adrenal axis stimulation. This is a preclinical finding in swine and has not been established in large human clinical trials.

Are ipamorelin and CJC-1295 studied together in the research literature?

Yes. Because GHS-R1a (ipamorelin’s target) and GHRHR (CJC-1295’s target) are two distinct stimulatory receptors on the same pituitary somatotroph cells, researchers have examined the co-administration of GHRH analogs and GHRPs as a model for studying additive stimulation of both GH-axis pathways simultaneously. This dual-pathway research framework reflects the established dual-receptor architecture of pituitary GH secretion. It is a documented research-literature observation, not a recommendation for human administration or protocol guidance of any kind.

For educational and research reference purposes only. Not medical advice. Not for human use. This article documents published scientific literature and is not intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.

TL;DR: GHRP-6, GHRP-2, and ipamorelin are all synthetic GHS-R1a agonists, they stimulate pulsatile growth hormone release by binding the same G protein-coupled receptor first cloned by Howard et al. in 1996. The three compounds differ substantially in selectivity: GHRP-6 produces documented orexigenic effects and significant ACTH/cortisol elevation in human studies; GHRP-2 is more potent for GH release but similarly non-selective, also elevating ACTH, cortisol, and prolactin; ipamorelin is documented as the first GHS-R1a agonist with GH-release selectivity comparable to GHRH, without significant ACTH or cortisol response at GH-releasing doses in preclinical swine models. None of the three are FDA approved, and all are prohibited by WADA under Section S2.

Research-Use Disclaimer: This article is for educational and research reference purposes only. GHRP-6, GHRP-2, and ipamorelin are research compounds, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research or limited human pharmacology studies. For adults 21+ with a research interest only.

What Is the Shared GHS-R1a Mechanism?

Growth hormone-releasing peptides (GHRPs) belong to the broader growth hormone secretagogue (GHS) class, compounds that stimulate GH release through a receptor pathway distinct from the classical GHRH receptor. The receptor target shared by GHRP-6, GHRP-2, and ipamorelin is designated GHS-R1a (growth hormone secretagogue receptor type 1a).

GHS-R1a was first cloned and characterized in a landmark 1996 study by Howard et al. published in Science. According to PubMed, the study identified GHS-R1a as a Gq/11-coupled G protein-coupled receptor (GPCR) expressed in the pituitary gland and the arcuate/ventromedial/infundibular regions of the hypothalamus in both swine and humans. Howard et al. demonstrated that GHS-R1a defines a distinct neuroendocrine pathway for the control of pulsatile GH release and that the GH secretagogues appeared to mimic an undiscovered endogenous hormone, a prediction confirmed four years later when ghrelin was identified as the receptor’s natural ligand.

When GHS-R1a is activated by any of these three GHRPs, the downstream result is episodic, pulsatile GH secretion from anterior pituitary somatotroph cells. This shared mechanism is why all three compounds are studied in the same GH-axis research context. The divergence lies not in the receptor activated, but in which other receptors and hormone axes are engaged simultaneously, and to what degree.

Three-Way Comparison Matrix

The table below summarizes the key pharmacological distinctions across GHRP-6, GHRP-2, and ipamorelin as documented in the peer-reviewed literature. See the individual compound sections below for citations and detail on each dimension.

GHRP-6: Documented Pharmacology and ACTH/Cortisol Profile

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It is one of the earliest and most studied members of the GHRP class, and much of the foundational research establishing the ACTH/cortisol effect of GHRPs was conducted using GHRP-6 as the reference compound.

According to PubMed, a 1995 randomized controlled trial by Frieboes et al., published in Neuroendocrinology, administered repetitive intravenous boluses of GHRP-6 to normal male subjects during the nocturnal period. The study found that GHRP-6 significantly elevated GH concentrations, but also raised ACTH and cortisol levels significantly compared to placebo, with nocturnal cortisol more than doubling in the GHRP-6 condition (56.0 ± 31.0 ng/mL vs. 25.2 ± 9.0 ng/mL, P < 0.02). This was a critical early demonstration that GHRP-6 engages the hypothalamic-pituitary-adrenocortical (HPA) axis in humans, an effect not observed with GHRH, which in fact blunts cortisol. The study described GHRP-6’s action on the HPA axis as opposite to that of GHRH.

A follow-up study by Frieboes et al. (1999), published in the Journal of Neuroendocrinology, explored different routes of GHRP-6 administration and found that intranasal GHRP-6 prompted significant GH increase and a trend toward elevated ACTH, while oral administration produced no significant GH, ACTH, or cortisol changes, demonstrating that the HPA activation is present at pharmacologically active doses and route-dependent.

GHRP-6’s orexigenic properties have been documented in the preclinical literature as a feature of GHS-R1a activation more broadly. The receptor is expressed in hypothalamic regions associated with appetite regulation, and GHRP-6 specifically has been associated with increased food intake in animal models via NPY/AgRP pathway engagement, a distinguishing feature not prominently documented for ipamorelin. This orexigenic effect is mechanistically connected to the same GHS-R1a receptor that mediates GH release, not a separate pharmacological target.

In a 2010 randomized controlled trial by de Sá et al., published in Metabolism, GHRP-6 and ghrelin were both administered intravenously to patients with type 1 diabetes and healthy controls. The study found that ghrelin-induced GH release was higher than that after GHRP-6 in both groups, and that ACTH and cortisol release after ghrelin and GHRP-6 were similar, with neither the GH nor the ACTH/cortisol responses significantly different between T1DM patients and controls. This study established that GHRP-6’s HPA axis engagement is a consistent pharmacological property not altered by diabetic metabolic context.

GHRP-2: High Potency, Non-Selective Profile

GHRP-2 (also called KP-102 or pralmorelin; sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) is a second-generation synthetic GHRP with substantially higher GH-releasing potency than GHRP-6, while retaining a similarly non-selective side-effect profile. It was among the most extensively studied GHRPs in human clinical pharmacology and remains in use as a diagnostic GH-stimulation tool in Japan under the name pralmorelin.

The potency advantage of GHRP-2 over GHRP-6 was quantified in the Raun et al. (1998) swine study: GHRP-2 demonstrated an in vivo GH-releasing ED50 of approximately 0.6 nmol/kg, roughly 6-fold more potent than GHRP-6 (ED50 ~3.9 nmol/kg) at equivalent maximum GH output. In vitro pituitary cell assays in the same study showed a similar potency advantage for GHRP-2.

However, GHRP-2’s non-selectivity is documented in human studies. According to PubMed, a 1997 comparative study by Arvat et al., published in Peptides, administered GHRP-2 and hexarelin to normal young and elderly adults and measured GH, prolactin, ACTH, and cortisol responses in comparison to GHRH, TRH, and human CRH. The study found that both GHRP-2 and hexarelin induced significant ACTH and cortisol responses with a magnitude comparable to that of human CRH, alongside their GH-releasing effects, and also elevated prolactin, though at lower levels than TRH. The authors concluded that GHRP-2 is “not fully specific” as it induces similar increases in prolactin, ACTH, and cortisol at doses required for GH release in humans.

A separate pharmacological characterization study of KP-102 (GHRP-2) by Doi et al. (2004), published in Arzneimittelforschung, used in vivo and in vitro models across rats and dogs. The study confirmed that KP-102 stimulated ACTH and corticosterone secretion in conscious rats alongside GH, but did not significantly affect prolactin, and demonstrated that its GH-releasing activity was less sensitive to somatostatin suppression than GHRH, operating partly through hypothalamic and partly through direct pituitary mechanisms. The study further documented growth-accelerating effects over three weeks in rats, consistent with the sustained GH-stimulating activity of GHRP-2.

Ipamorelin: Selectivity as a Pharmacological Distinction

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide developed at Novo Nordisk and first described in the literature in 1998. It differs structurally from GHRP-6 and GHRP-2 in lacking the central Ala-Trp dipeptide sequence found in GHRP-1 from which both older compounds are derived. This structural difference is associated with its distinct selectivity profile at GHS-R1a.

The foundational selectivity characterization was performed in the Raun et al. (1998) study in the European Journal of Endocrinology. According to PubMed, this study systematically compared ipamorelin, GHRP-6, and GHRP-2 across GH, FSH, LH, PRL, TSH, ACTH, and cortisol responses in swine. The critical finding: ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation alone, even at doses more than 200-fold higher than the GH-releasing ED50, while both GHRP-6 and GHRP-2 produced significant ACTH and cortisol elevations at standard GH-releasing doses. FSH, LH, prolactin, and TSH were unaffected by all three GHSs. The authors described ipamorelin as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.”

This selectivity profile distinguishes ipamorelin as a pharmacological research tool for isolating GHS-R1a-mediated GH effects from the HPA-axis co-stimulation seen with less selective GHRPs. It is important to note this finding originated in a swine model and has not been replicated in large, controlled human efficacy trials. The existing human pharmacokinetic data (Gobburu et al., 1999) documented ipamorelin’s PK parameters and GH-releasing profile in healthy male volunteers but did not measure ACTH or cortisol endpoints. For the full ipamorelin compound profile, see the dedicated post: What Is Ipamorelin? Mechanism and Evidence.

How Does Selectivity Differ? The Mechanistic Explanation

The selectivity differences among these three compounds reflect the structural pharmacology of GHS-R1a activation and the divergent downstream signaling consequences of different ligand-receptor interaction geometries, a concept sometimes called “biased agonism.”

GHS-R1a is a Gq/11-coupled GPCR. Its activation by ghrelin, GHRP-6, or GHRP-2 engages not only pituitary somatotrophs but also hypothalamic neurons that regulate CRH secretion, the upstream driver of the HPA axis. GHRP-6 and GHRP-2 appear to activate both somatotroph GHS-R1a (GH pulse) and CRH-neuronal GHS-R1a (ACTH/cortisol) with similar efficacy. Ipamorelin’s structural modifications, specifically the Aib N-terminal residue and lack of the Ala-Trp dipeptide, appear to confer a binding geometry that produces equivalent somatotroph activation with substantially reduced HPA-axis co-stimulation. The precise molecular mechanism underlying this selectivity difference remains an active area of investigation.

GHRP-6’s additional orexigenic effect is mechanistically linked to GHS-R1a expression in the hypothalamic arcuate nucleus, where activation interacts with NPY/AgRP circuits. This is a shared property of GHS-R1a agonism broadly, but appears more pronounced with GHRP-6 than with more selective compounds, consistent with GHRP-6’s less discriminating receptor engagement profile.

For a broader overview of the GH axis and all GHS compounds covered in the Legendary Labz guide, see the GH Axis & Secretagogues cluster overview and the mechanism comparisons pillar.

Evidence by Tier: What the Research Base Actually Shows

All three compounds sit at Tier 2 in the Legendary Labz evidence framework, but the nature and depth of their respective evidence bases differ meaningfully. For methodology, see How to Read an Evidence Tier.

Critical limitation applicable to all three compounds: preclinical pharmacology findings, including the pivotal selectivity data for ipamorelin and the ACTH/cortisol effect data for GHRP-6 and GHRP-2, were obtained in animal models (predominantly rats and swine) or in short-duration human pharmacology studies. These findings do not establish efficacy or safety for any therapeutic endpoint in humans. The degree to which preclinical selectivity profiles translate to human physiology remains scientifically unestablished. No large, placebo-controlled, long-term human efficacy RCTs have been published for any of these three compounds as of 2026.

Regulatory and Anti-Doping Status

FDA (United States)

None of the three compounds, GHRP-6, GHRP-2, or ipamorelin, are approved by the U.S. Food and Drug Administration as drugs, biologics, or dietary supplement ingredients. None have authorized human dosing protocols or approved indications in the United States. Pralmorelin (GHRP-2) has regulatory approval in Japan solely as a diagnostic agent for GH stimulation testing, not as a therapeutic. Researchers should consult current FDA guidance directly regarding the classification and regulatory status of each compound.

WADA (World Anti-Doping Agency)

All three compounds are prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List. Section S2 covers all GH-releasing peptides and mimetics. The prohibition applies both in-competition and out-of-competition for athletes subject to WADA rules. WADA has developed detection methodology for GHRPs in biological samples; researchers designing doping control studies should consult the current WADA Technical Document.

Frequently Asked Questions

What is the main difference between GHRP-6, GHRP-2, and ipamorelin?

All three are GHS-R1a agonists that stimulate pulsatile GH release, but they differ substantially in selectivity. In the landmark 1998 Raun et al. study in the European Journal of Endocrinology, ipamorelin did not significantly elevate ACTH or cortisol in swine even at doses more than 200-fold above its GH-releasing ED50, while both GHRP-6 and GHRP-2 produced significant ACTH and cortisol responses at standard GH-releasing doses. GHRP-6 additionally demonstrates orexigenic effects not prominently observed with ipamorelin. This is a preclinical selectivity distinction and has not been confirmed in large-scale human trials.

Does GHRP-6 raise cortisol?

Yes, based on published human data. The 1995 Frieboes et al. randomized controlled trial (PMID 7617137, Neuroendocrinology) documented significant nocturnal cortisol elevation after intravenous GHRP-6 in healthy men, more than double placebo levels. This HPA-axis engagement is a consistent finding across multiple GHRP-6 studies and distinguishes GHRP-6 from both GHRH and ipamorelin in the published pharmacology literature.

Is ipamorelin more selective than GHRP-2?

Based on current evidence, yes. Raun et al. (1998) showed no significant ACTH or cortisol elevation with ipamorelin at doses 200-fold above the GH ED50 in swine. Arvat et al. (1997) documented that GHRP-2 produces ACTH and cortisol responses in humans comparable to human CRH in magnitude. Ipamorelin’s selectivity advantage is a preclinical finding; it has not been formally compared to GHRP-2 in a controlled human pharmacology trial measuring both GH and HPA-axis endpoints.

Are GHRP-6, GHRP-2, and ipamorelin prohibited by WADA?

Yes. All three are prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List, both in-competition and out-of-competition, for all athletes subject to WADA anti-doping rules.

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: GHK-Cu (glycyl-L-histidyl-L-lysine-copper) and BPC-157 (Body Protection Compound-157) are both studied in tissue-repair research contexts, but operate through mechanistically distinct pathways. GHK-Cu is a naturally occurring copper-chelating tripeptide documented for extracellular matrix (ECM) remodeling, stimulating collagen and glycosaminoglycan synthesis and broadly modulating gene expression, with a meaningful body of in vitro and cosmetic-use human data. BPC-157 is a synthetic 15-amino acid pentadecapeptide documented for context-sensitive angiogenesis, VEGF upregulation, ERK1/2 signaling, and nitric oxide system interaction, supported predominantly by preclinical rodent studies. Neither compound is FDA-approved as a drug. This article compares the two at the mechanism and evidence level only.

Research-Use Disclaimer: This article is for educational and research reference purposes only. GHK-Cu and BPC-157 are research compounds not approved by the FDA for human therapeutic use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings below refer to published preclinical or cosmetic-use research. For adults 21+ with a research interest only.

Quick Comparison: GHK-Cu vs BPC-157 at a Glance

The table below summarizes the key structural, mechanistic, and regulatory differences between the two compounds as documented in published scientific literature. Detailed mechanism analysis follows.

GHK-Cu: How the Copper-Peptide ECM Remodeling Mechanism Works

GHK-Cu functions as a copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). The parent tripeptide GHK occurs naturally in human plasma, averaging approximately 200 ng/mL at age 20 and declining to roughly 80 ng/mL by age 60, and was first isolated in 1973 by Loren Pickart, who identified it as a factor in human albumin that caused aged liver tissue to synthesize proteins at rates resembling younger tissue. The copper(II) chelate, GHK-Cu, is the biologically active form documented across the connective tissue and wound-healing literature.

Collagen and Glycosaminoglycan Stimulation

The landmark preclinical demonstration of GHK-Cu’s ECM activity comes from a 1993 rat wound-chamber study by Maquart et al., published in the Journal of Clinical Investigation. Using subcutaneous stainless-steel mesh cylinders implanted in rats, the researchers found that GHK-Cu injections produced a concentration-dependent increase in dry weight, total protein, collagen, DNA, and glycosaminoglycan content in the wound chamber. Collagen synthesis was stimulated at twice the rate of non-collagen proteins. Critically, type I and type III collagen mRNAs were elevated, but TGF-β mRNAs were not, implying a mechanism distinct from classical TGF-β-mediated collagen induction (PMID: 8227353).

A 2000 follow-up study by Siméon, Wegrowski, and Maquart in the Journal of Investigative Dermatology extended these findings to glycosaminoglycan and small proteoglycan regulation in rat wound chambers and dermal fibroblast cultures. GHK-Cu treatment increased accumulation of chondroitin sulfate and dermatan sulfate in wound tissue, upregulated decorin mRNA, and downregulated biglycan mRNA, demonstrating that the compound’s ECM influence extends beyond collagen to the broader proteoglycan and glycosaminoglycan architecture of healing tissue (PMID: 11121126).

Gene Expression Modulation

A 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences synthesized decades of in vitro and in vivo research, describing GHK as capable of regulating multiple biochemical pathways via broad gene expression modulation, including genes involved in collagen synthesis, metalloproteinase activity, antioxidant defense, nerve outgrowth, and blood vessel formation. The authors noted GHK’s ability to improve tissue repair across skin, lung connective tissue, bone, liver, and stomach lining in preclinical models, attributing the compound’s diverse actions to its capacity to interact with a wide gene regulatory network (PMID: 29986520).

Angiogenic Activity via ECM Context

GHK-Cu has also been associated with angiogenic markers, though this appears secondary to its ECM-remodeling function rather than a primary angiogenic drive. A 2022 study by Yang et al. in Macromolecular Bioscience used a GHK-functionalized hydrogel scaffold in healthy and diabetic mouse wound models, reporting significantly accelerated wound closure, increased collagen deposition, tissue remodeling, and upregulated eNOS and CD31 expression in the treatment group (PMID: 35598070). The angiogenic markers here emerged alongside the ECM remodeling effect, reflecting a coordinated wound-repair response rather than isolated angiogenic induction.

An earlier rat wound model by Arul et al. (2005, Journal of Biomedical Materials Research) using biotinylated GHK peptide incorporated into a collagen membrane demonstrated enhanced wound contraction, increased cell proliferation, elevated antioxidant enzyme expression, and a ninefold increase in copper concentration at the wound site, linking copper localization to the compound’s wound-healing properties (PMID: 15803494).

BPC-157: How the Body-Protective Angiogenesis and NO Mechanism Works

BPC-157 is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. Unlike GHK-Cu, it is not endogenously circulating at measurable plasma levels; it is entirely synthetic and does not decline with age in the same manner. Its research literature, originating largely from Predrag Sikiric’s group at the University of Zagreb over three decades, describes it as a pleiotropic agent acting across multiple biological systems simultaneously.

VEGF Upregulation and ERK1/2 Signaling

One of the most thoroughly documented preclinical mechanisms for BPC-157 is its capacity to upregulate VEGF (vascular endothelial growth factor) expression and activate downstream angiogenic signaling. A 2015 study by Huang et al. in Drug Design, Development and Therapy investigated BPC-157 in an alkali-burn rat model and human umbilical vein endothelial cell (HUVEC) assays, finding that BPC-157 upregulated VEGF-a expression, enhanced HUVEC proliferation and migration, accelerated vascular tube formation in vitro, and regulated ERK1/2 phosphorylation and its downstream targets (c-Fos, c-Jun, Egr-1), molecules associated with cell growth, migration, and angiogenesis. In vivo, BPC-157-treated wounds showed better granulation tissue formation, reepithelialization, and higher collagen deposition compared to controls (PMID: 25995620).

Nitric Oxide System Interaction

A defining characteristic of BPC-157 in the research literature is its interaction with the nitric oxide (NO) system. A 2006 review by Sikiric et al. in Inflammopharmacology, covering BPC-157’s human clinical trial history (two early-phase trials for inflammatory bowel disease under designations PL-10 and PL 14736, with no reported toxicity), described BPC-157’s documented effects on the nitric oxide system, endothelium protection, endothelin modulation, and angiogenesis promotion in preclinical models. The review also documented BPC-157’s stability in gastric juice, its gastroprotective and cytoprotective properties, and its apparent multi-organ applicability in rodent models (PMID: 17186181).

A 2025 commentary by Sikiric et al. in Pharmaceuticals further addressed the mechanistic debate around BPC-157’s NO involvement, arguing that the compound’s distinctive feature is its capacity to target both cytotoxic and damaging NO actions while maintaining or recovering NO’s essential protective functions, a bidirectional modulation that may explain its apparent cytoprotective effects across multiple tissue types (PMID: 41155565).

Musculoskeletal and Soft Tissue Repair

A 2019 review by Gwyer, Wragg, and Wilson at Loughborough University in Cell and Tissue Research critically examined the BPC-157 musculoskeletal literature, noting that all studies investigating BPC-157 have demonstrated consistently positive healing effects for various soft tissue injury types in rodent models, including tendon, ligament, and skeletal muscle. The review acknowledged the significant limitation that “to date, only a handful of research groups have performed in-depth studies regarding this peptide, ” and that all data remains in small rodent models with no human RCT confirmation (PMID: 30915550).

How GHK-Cu and BPC-157 Differ at the Mechanism Level

Despite both compounds appearing in tissue-repair research contexts, their documented mechanisms diverge sharply in several respects.

Source and endogenous status. GHK-Cu is a naturally occurring tripeptide present in human plasma, saliva, and urine throughout life, it has an endogenous reference point and a measurable age-related decline. BPC-157 is entirely synthetic; it is derived from a gastric protein but not found circulating at measurable systemic levels. This distinction matters for how researchers interpret their respective preclinical data.

Primary action site. GHK-Cu’s documented primary actions are at the extracellular matrix level, it acts on fibroblasts, regulates collagen and proteoglycan gene expression, and reshapes the structural scaffolding of connective tissue. BPC-157’s documented primary actions are vascular and cytoprotective, it drives angiogenic signaling, interacts with the NO pathway, and appears to accelerate tissue repair by improving blood supply and cellular survival rather than by directly rebuilding matrix architecture.

Evidence breadth vs. depth. GHK-Cu’s research base is broader in terms of tissue types and experimental models, and it has meaningfully more human-adjacent data through its cosmetic-ingredient regulatory pathway. BPC-157’s research base is deeper in rodent soft-tissue injury models, with consistent findings across tendon, ligament, gut, and muscle, but remains almost entirely preclinical and concentrated in a small number of research groups.

Regulatory divergence. GHK-Cu is an established cosmetic ingredient regulated by the FDA in topical formulations, a status that implies extensive safety review for dermal application, though not systemic or injectable use. BPC-157 has no regulatory approval pathway; it is explicitly listed on the WADA Prohibited List under Section S0.

Evidence Tier Assessment: Both Are Largely Preclinical

Despite the mechanistic differences above, GHK-Cu and BPC-157 share a critical limitation: neither has been validated in large, placebo-controlled human randomized controlled trials for any tissue-repair or therapeutic indication. The following table maps the evidence landscape for both.

A critical methodological note on BPC-157: The Gwyer et al. (2019) review explicitly flags a limitation rarely emphasized in popular discussions of BPC-157, the vast majority of published studies originate from a single research group. Independent replication by multiple laboratories is a cornerstone of scientific validation, and its relative absence in the BPC-157 literature means the findings, while internally consistent, carry greater uncertainty than would a similarly-sized body of evidence produced across independent institutions. The GHK-Cu literature, by contrast, includes independently replicated findings across research groups in France, India, China, and the United States, across multiple decades.

Frequently Asked Questions: GHK-Cu vs BPC-157

What is the primary mechanism difference between GHK-Cu and BPC-157?

GHK-Cu operates primarily through copper-mediated extracellular matrix remodeling, stimulating collagen and glycosaminoglycan synthesis, modulating matrix metalloproteinases, and broadly regulating gene expression in fibroblast and wound-chamber models. BPC-157 operates primarily through context-sensitive angiogenesis modulation, documented VEGF upregulation, ERK1/2 signaling, and interactions with the nitric oxide system in preclinical injury models. Both are studied in tissue-repair contexts but through mechanistically distinct pathways.

Which compound has more human evidence, GHK-Cu or BPC-157?

GHK-Cu has a larger body of human-adjacent data, primarily from its regulated use as a cosmetic ingredient, including topical-use observations in dermatology and small-scale skin studies. BPC-157 has been referenced in two early-phase human trials for gastrointestinal indications with no reported toxicity, but no large placebo-controlled human RCTs for tissue repair exist for either compound as of 2026. Both are predominantly supported by preclinical evidence.

Are GHK-Cu and BPC-157 approved by the FDA?

Neither compound is FDA-approved as a drug for any therapeutic indication. GHK-Cu is regulated as a cosmetic ingredient in topical formulations in the United States; it has no approved drug indication and no authorized human therapeutic dosing protocol. BPC-157 is not approved by the FDA for any use in humans. It is listed under WADA Section S0 (Non-Approved Substances). GHK-Cu is not specifically named on the 2026 WADA Prohibited List, though athletes subject to WADA rules should verify annually.

Do GHK-Cu and BPC-157 share any overlapping mechanisms?

The peer-reviewed literature documents some overlap: both compounds have been associated with VEGF expression and angiogenic markers in preclinical models, and both show activity in wound-healing contexts. However, the pathways diverge significantly: GHK-Cu’s angiogenic effects appear secondary to ECM remodeling and copper-mediated gene regulation, while BPC-157’s angiogenic activity is linked to ERK1/2 and nitric oxide signaling. The two compounds have not been directly compared head-to-head in a single published study as of 2026.

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: PT-141 (bremelanotide) is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone, studied as an agonist at the melanocortin MC3R and MC4R receptors with documented CNS-mediated activity. Its pharmaceutical form, Vyleesi, received FDA approval in 2019 following two Phase 3 RECONNECT trials. Research-grade PT-141 is a separate, non-approved compound subject to full research-use classification. WADA status: prohibited.

Research-Use Disclaimer: This article is for educational and research reference purposes only. PT-141 (bremelanotide) in research-grade form is not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any research compound, and does not describe protocols for personal use. All study findings described below refer to published peer-reviewed research. For adults 21+ with a research interest only.

What Is PT-141 (Bremelanotide)? Definition and Origins

PT-141, known in the pharmaceutical literature as bremelanotide, is a synthetic cyclic heptapeptide, a seven-amino-acid chain, derived as a structural analogue of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous neuropeptide produced from the precursor protein pro-opiomelanocortin (POMC). Its chemical designation is cyclo-[Nle⁴, D-Phe⁷]-α-MSH(4–10), and it shares a core sequence with the earlier research compound Melanotan II.

The distinction between PT-141/bremelanotide and Melanotan II is structurally meaningful: bremelanotide is a direct metabolite of Melanotan II, formed by the loss of the C-terminal amide. In the peer-reviewed development review published in Drugs by Dhillon and Keam (2019), the authors document that this structural modification eliminated the melanogenic (skin-tanning) activity associated with Melanotan II while retaining the compound’s high-affinity binding at melanocortin receptor subtypes MC3R and MC4R, the receptors implicated in its CNS-mediated pharmacological profile. The compound was developed by Palatin Technologies under the research designation PT-141 before entering clinical trials as bremelanotide, and subsequently out-licensed to AMAG Pharmaceuticals for North American commercialization.

How Does PT-141 Work? The MC3R / MC4R Receptor Mechanism

PT-141 (bremelanotide) produces its documented pharmacological effects by acting as an agonist at two members of the melanocortin receptor family, MC3R (melanocortin type 3 receptor) and MC4R (melanocortin type 4 receptor). Both are G protein-coupled receptors (GPCRs) expressed in the central nervous system, with MC4R particularly concentrated in the hypothalamus, brainstem, and limbic structures. This CNS localization distinguishes bremelanotide’s mechanism from compounds that act peripherally on vascular or gonadal tissue.

What Does MC4R Agonism Produce in the CNS?

MC4R is one of five known melanocortin receptor subtypes encoded in the human genome. In addition to its roles in energy homeostasis and appetite regulation, MC4R is expressed in brain regions associated with motivational and autonomic processes. A 2006 Phase 2 randomized controlled trial by Diamond et al., published in the Journal of Sexual Medicine, documented that a single intranasal dose of bremelanotide produced significantly more self-reported changes in subjective response compared to placebo in 18 premenopausal subjects with a diagnosed sexual arousal disorder, and characterized the mechanism as operating through MC3R and MC4R agonism modulating brain pathways involved in the autonomic sexual response, distinct from the peripheral vascular mechanism of phosphodiesterase-5 inhibitors. This CNS pathway emphasis is consistent with the compound’s receptor pharmacology: unlike peripherally acting vasodilators, bremelanotide targets hypothalamic and limbic receptor populations that are upstream of downstream physiological responses.

The Relationship Between MC4R Agonism and Blood Pressure

MC4R agonism has a documented cardiovascular correlate: transient increases in blood pressure. A randomized, double-blind, placebo-controlled ambulatory blood pressure monitoring trial by White et al. (2017), published in the Journal of Hypertension, enrolled 397 subjects across three dose levels of bremelanotide and found that bremelanotide produced statistically significant, dose-dependent increases in systolic blood pressure of 2.4–3.1 mmHg above placebo, accompanied by reductions in heart rate, during the 0–4 hour post-dose interval, with peak increases typically lasting less than 15 minutes. The authors noted that this cardiovascular signal, a reflex bradycardia pattern consistent with MC4R-mediated sympathetic activation, was one of the key findings that informed blood pressure monitoring requirements in the subsequent larger Phase 3 trials. This is not a secondary or incidental observation: the MC4R receptor’s role in autonomic regulation means cardiovascular effects are mechanistically linked to the same receptor target responsible for the compound’s studied primary effects.

A comprehensive review by Bardhan et al. (2025) in Diseases, covering the genetics and pharmacology of melanocortin receptor subtypes, contextualizes the broader melanocortin receptor family, noting that MC4R mutations are associated with monogenic obesity in humans, and that the FDA has approved multiple melanocortin agonists targeting different receptor subtypes for distinct indications, confirming bremelanotide’s place within a pharmacologically validated receptor class.

What Does the Bremelanotide Research Show?

The RECONNECT Phase 3 Trials

The most rigorous peer-reviewed evidence for bremelanotide’s pharmacological activity in human subjects comes from the two identically designed RECONNECT Phase 3 trials, published by Kingsberg et al. in Obstetrics and Gynecology in 2019. These multicenter, randomized, double-blind, placebo-controlled studies (ClinicalTrials.gov NCT02333071 and NCT02338960) enrolled 1, 247 subjects randomized 1:1 to bremelanotide 1.75 mg subcutaneous or placebo for 24 weeks. Both studies demonstrated statistically significant improvements in co-primary efficacy endpoints: Female Sexual Function Index desire domain score (Study 301: +0.30, P<0.001; Study 302: +0.42, P<0.001) and Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13 (Study 301: −0.37, P<0.001; Study 302: −0.29, P=0.005). Treatment-emergent adverse events, nausea (≈40%), flushing (≈20%), and headache (≈11%), were substantially more common in the bremelanotide arm than placebo.

Safety Profile Across the Clinical Program

A systematic review of bremelanotide’s safety data across the full clinical development program (43 completed studies, approximately 3, 500 subjects) was published by Clayton et al. (2022) in the Journal of Women’s Health. The review documented that the most common adverse events in the integrated double-blind Phase 3 population (n=1, 247) were nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4% vs. 0.5%). No deaths were attributed to bremelanotide. Focal hyperpigmentation, a mechanistically expected consequence of melanocortin receptor activation, occurred in more than one-third of subjects in studies involving up to 16 consecutive daily doses, though was rare at label-recommended dosing intervals. Transient blood pressure increases were confirmed across the program, leading to cardiovascular monitoring recommendations in the prescribing label.

RECONNECT Subgroup Analyses

A pre-specified subgroup analysis of the RECONNECT pooled population by Simon et al. (2022), published in the Journal of Women’s Health, evaluated efficacy by age, weight, BMI, baseline bioavailable testosterone quartile, and hormonal contraceptive use. Bremelanotide achieved statistically significant improvements in desire and distress reduction across all age, weight, and BMI subgroups, and across all baseline testosterone quartiles, with few exceptions, reinforcing the MC4R-mediated CNS mechanism as a pathway operating with relative independence from circulating androgen levels. This finding is pharmacologically relevant because it suggests the documented effect operates upstream of the hormonal axes that typically drive androgen-dependent responses.

Early-Phase Receptor Pharmacology and Clinical Framing

A 2020 systematic review by Mayer and Lynch published in Annals of Pharmacotherapy, reviewing Phase 2 and Phase 3 trial data in context of bremelanotide’s FDA approval, characterized the compound as a melanocortin 4 receptor agonist whose Phase 3 trials met statistical significance for their co-primary endpoints, while noting that the clinical magnitude of effect was modest, a characterization consistent with the RECONNECT trial effect sizes, which were statistically significant but numerically small on the scales used. This honest representation of effect magnitude is important context for researchers evaluating the compound’s evidence tier.

The FDA Approval of Bremelanotide (Vyleesi): Regulatory Record

As documented regulatory fact: the U.S. FDA approved bremelanotide, marketed as Vyleesi by AMAG Pharmaceuticals, in June 2019 for a specific indication. The approval was based on the RECONNECT Phase 3 data and the complete clinical development program. This makes bremelanotide one of a small number of peptide-class compounds with a formally approved pharmaceutical application, placing it in a distinct regulatory category from compounds like BPC-157 or Ipamorelin, which have no approved human therapeutic use in any jurisdiction. The Dhillon and Keam (2019) Drugs approval review, indexed at PMID 31429064, documents the regulatory milestones through FDA approval.

Critical distinction for researchers: The FDA approval applies specifically to the pharmaceutical product Vyleesi (bremelanotide 1.75 mg subcutaneous injection, manufactured under pharmaceutical GMP) for the approved indication, in the approved patient population, under medical supervision. Research-grade PT-141 purchased through research supply channels is not the same as Vyleesi, has not undergone pharmaceutical manufacturing controls, and is classified as an unapproved research compound for non-human use. The existence of an FDA-approved pharmaceutical analogue does not alter the research-use classification of non-pharmaceutical-grade material.

Evidence Tier: An Honest Assessment

Bremelanotide/PT-141 occupies an unusual position in the research peptide landscape, it is the only compound in the common research peptide set with a direct pharmaceutical equivalent that has completed Phase 3 trials and received FDA approval. This affects how its evidence tier should be read:

The limitation to state plainly: The Phase 3 RECONNECT trial effect sizes, while statistically significant, were numerically modest on the validated scales used. The Mayer and Lynch (2020) systematic review noted that “the clinical benefit may only be modest.” Statistically significant group differences in controlled trials do not translate automatically to large individual-level effects. Researchers should read the primary trial publications, not summaries, to accurately understand the magnitude of documented outcomes.

Regulatory and WADA Status

FDA (United States)

The FDA-approved pharmaceutical bremelanotide (Vyleesi) is a prescription drug available through licensed healthcare providers for the approved indication. Research-grade PT-141 sourced outside the pharmaceutical supply chain is not FDA approved for any human therapeutic use. The FDA evaluates products, not compounds in isolation; the existence of an approved pharmaceutical form does not grant approval to non-pharmaceutical-grade material. Researchers should consult current FDA guidance and their institutional review protocols directly.

WADA (World Anti-Doping Agency)

WADA classifies bremelanotide/PT-141 under Section S0: Non-Approved Substances when used outside the context of a lawful medical prescription. S0 covers any pharmacological substance used in a manner not consistent with an authorized regulatory approval. Athletes subject to WADA rules, even those with a legitimate medical prescription, should consult their national anti-doping authority regarding Therapeutic Use Exemption (TUE) requirements before any use. The prohibition applies both in-competition and out-of-competition.

Relationship to the Melanocortin System and Related Compounds

Bremelanotide’s receptor targets, MC3R and MC4R, are part of a five-receptor family (MC1R through MC5R) that evolved as mediators of diverse physiological functions downstream of POMC cleavage products, including adrenocorticotropic hormone (ACTH), α-MSH, β-MSH, and γ-MSH. The Bardhan et al. (2025) review in Diseases documents that MC4R is also implicated in monogenic obesity, energy homeostasis, and inflammatory regulation in preclinical models, illustrating that bremelanotide’s studied indication represents only one research application of a pharmacologically rich receptor class.

Researchers situating bremelanotide within a broader hormonal research context may also find value in reviewing the Kisspeptin profile, a neuropeptide that operates within the GnRH-LH-FSH reproductive axis, providing a distinct but related CNS-hormonal research reference point, and the hormonal peptide cluster overview in the Research Journal. For methodology on evaluating the evidence quality of any compound profile, see How to Read an Evidence Tier.

Frequently Asked Questions About PT-141 (Bremelanotide)

What is PT-141 (bremelanotide) and how does it differ from Melanotan II?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of α-MSH and a direct metabolite of Melanotan II. The structural difference, loss of the C-terminal amide, eliminates Melanotan II’s melanogenic (tanning) activity while preserving MC3R and MC4R binding. Bremelanotide is the active pharmaceutical form developed through Palatin Technologies’ clinical program and received FDA approval in 2019 as Vyleesi. Melanotan II and research-grade PT-141 distributed outside the pharmaceutical supply chain are distinct, unapproved research compounds.

What did the RECONNECT Phase 3 trials of bremelanotide find?

The two RECONNECT trials (Kingsberg et al., 2019) enrolled 1, 247 subjects in randomized, double-blind, placebo-controlled 24-week studies. Both met co-primary efficacy endpoints: statistically significant improvements in the Female Sexual Function Index desire domain and Female Sexual Distress Scale Item 13. Effect sizes were modest in absolute terms. Treatment-emergent adverse events, nausea (≈40%), flushing (≈20%), headache (≈11%), occurred substantially more often in the active arm than placebo. These are the primary human efficacy data on record for this compound class.

Is bremelanotide (Vyleesi) FDA approved?

Yes, as a pharmaceutical drug for a specific indication. The FDA approved Vyleesi (bremelanotide) in June 2019 based on the RECONNECT Phase 3 trial data. This approval applies to the pharmaceutical product manufactured under GMP controls, dispensed by prescription for the approved indication. Research-grade PT-141 available through research supply channels is not the same product, is not FDA approved for human use, and carries full research-compound classification regardless of the pharmaceutical approval of its analogue.

Where is PT-141/bremelanotide on the WADA Prohibited List?

WADA classifies bremelanotide under Section S0: Non-Approved Substances for use outside an authorized medical prescription. The S0 category covers any pharmacological substance whose use is inconsistent with an applicable regulatory authorization. Athletes subject to WADA rules should consult the current Prohibited List and their anti-doping authority regarding Therapeutic Use Exemption procedures before any use.

For educational and research reference purposes only. Not medical advice. Not for human use. PT-141 (bremelanotide) in research-grade form is not approved by the FDA for human use. This article documents published scientific literature and regulatory records for educational and reference purposes only; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. The FDA approval of the pharmaceutical product Vyleesi applies specifically to that licensed pharmaceutical under medical supervision, it does not apply to research-grade material. All citations link to primary sources, read them in full. Must be 21+.